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Preface
 6 
 
 
 
 
 
 
The laboratory Signalisations Moléculaires et Neurodégénerescence headed 
by Dr Jean-Philippe Loeffler focuses its research on the neuronal death process that 
occurs in neurodegenerative diseases such as amyotrophic lateral sclerosis and 
Alzheimer's disease. To understand the mechanisms that trigger the neuronal 
degeneration, studies are performed both directly on patients affected by these 
diseases and on cellular or animal models that mimic in vitro or in vivo the neuronal 
degenerative process. 
My PhD work was dedicated to amyotrophic lateral sclerosis (ALS), also called 
"maladie de Charcot" in Europe or "Lou Gehrig's disease" in United-States. ALS is a 
progressive neurodegenerative disease that attacks nerve cells in the brain and 
spinal cord, and produces muscle weakness and atrophy. When I joined the team in 
2001, there was a general acceptance that ALS was an exclusive motor neuron 
pathology. Thus, investigations in the lab focused on gene expression changes 
occuring in the spinal cord. A differential screening approach, performed on a line of 
transgenic mice that develop an ALS-like syndrome, revealed strong genetic 
modifications in the spinal cord that already occurred in the absence of any overt 
symptoms. Interestingly, some of the modulated genes were also regulated in the 
skeletal muscles of these transgenic mice and were particularly relevant to ALS. 
These results, together with data from the litterature, not only highlighted the 
importance of studying the skeletal muscle tissue but also presaged an active 
contribution of this tissue to the disease process. These considerations prompted us 
to focus our attention on the skeletal muscle tissue in ALS. 
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 Abbreviations 
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AD:   Alzheimer's disease 
ALS:   amyotrophic lateral sclerosis 
ALSFRS:  ALS Functional Rating Scale 
ALSSS:  ALS Severity Scale 
BACE-1:  -amyloid converting enzyme 1 
CNS:   central nervous system 
CRABP-I:  retinoic acid binding protein I 
CSF:   cerebral spinal fluid 
CTWC:  Coupled Two-Way Clustering 
EDX:   electrodiagnostic 
ER:   endoplasmic reticulum 
ESTs:  expressed sequence tags 
FALS :  familial ALS 
FDG:   2-18F-2-deoxy-D-glucose 
FVC:   forced vital capacity 
GDNF:  glial cell line-derived neurotrophic factor 
GO:   Gene Ontology 
IGF-1:  insulin like growth factor-1 
KEGG:  Kyoto Encyclopedia of Genes and Genomes 
LINGO-1:  LRR and Ig domain-containing, Nogo Receptor-interacting protein 
MAS:   Microarray Analysis Suite 5.0 (Affymetrix) 
MM:   mismatch 
MMT:  manual muscle testing 
MRI:   magnetic resonance imaging 
MRS:   magnetic resonance spectroscopy 
MS:   multiple sclerosis 
MVIC:  maximal voluntary isometric contraction 
NAA:   N-acetyl aspartate 
NgR:   Nogo receptor 
NMJ:   neuromuscular junction 
OMIM:  Online Mendelian Inheritance in ManTM 
p75NTR:  p75 neurotrophin receptor 
PET:   positron emission tomography 
PM:   perfect match 
 9 
QPCR:  quantitative polymerase chain reaction 
RA:   retinoic acid 
RALDH-2:  retinaldehyde dehydrogenase-2 
RHD:   reticulon homolgy domain 
RMA:  Robust Multichip Average 
ROS:   reactive oxygen species 
RTN:   reticulon 
SALS:  sporadic ALS 
SCLC:  small-cell lung carcinoma 
SMN:   survival motor neuron 
SOD1:  Cu,Zn superoxide dismutase 
SPECT:  single photon emission tomography 
UCP:   uncoupling protein 
VAPB:  vesicle-associated membrane protein B 
VEGF:  vascular endothelial growth factor 
 10 
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Analysis of variance (ANOVA): a collection of parametric tests that compare 
means by splitting the overall observed variance into different parts. 
 
Data mining: the interpretation of microarray data towards the understanding 
of biological processes. 
 
Data quantitation: the translation of the signal intensities from microarrays 
into numerical values. 
 
Dendogram: a graphical form of representation of the similarities of gene 
expression. 
 
Expressed Sequence Tags (ESTs): partial cDNA "survey sequences". 
 
Fold approach: in this approach, a gene is declared to be turned "on" or "off", 
if the average expression level is increased or decreased respectively by a 
predetermined number of "folds". 
 
GenBank: the National Institutes of Health (NIH) genetic sequence database, 
an annotated collection of all publicly available DNA sequences. A new release is 
made every two months. GenBank is part of the International Nucleotide Sequence 
Database Collaboration, which is comprised of the DNA DataBank of Japan (DDBJ), 
the European Molecular Biology Laboratory (EMBL), and GenBank at the National 
Center for Biotechnology Information. These three organizations exchange data on a 
daily basis.  
 
Gene expression matrix: a tabular arrangement of gene expression profiles. 
 
Gene Expression Omnibus (GEO): a high-throughput gene expression / 
molecular abundance data repository, as well as a curated, online resource for gene 
expression data browsing, query and retrieval.  
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Gene Ontology (GO): a controlled vocabulary for describing genes, 
structured hierarchically as a directed acyclic graph (DAG), where nodes (or terms) 
are more general if closer to the root and more specific if closer to the leaf. 
 
GenMAPP: a free computer application designed to visualize gene expression 
and other genomic data on maps representing biological pathways and groupings of 
genes. 
 
Heuristic algorithm: two fundamental goals in computer science are finding 
algorithms with provably good run times and with provably good or optimal solution 
quality. A heuristic algorithm gives up one or both of these goals; for example, it 
usually finds pretty good solutions, but there is no proof the solutions could not get 
arbitrarily bad. 
 
HG-U133 Target Databank: a compilation of probeset annotations and target 
sequence information for all the probes represented on the human genome HG-U133 
A and B arrays. 
 
Hybridization: the process whereby two complementary DNA or RNA strands 
join to form a double stranded structure. 
 
Kruskal-Wallis test: a non-parametric test used to compare three or more 
independent groups of sampled data. It uses the ranks of the data rather than their 
raw values to calculate the statistic. 
 
Kyoto Encyclopedia of Genes and Genomes (KEGG): a suite of databases 
and associated software, integrating our current knowledge on molecular interaction 
networks in biological processes ("pathway" database), the information about the 
universe of genes and proteins ("genes"/"ssdb"/"ko" databases), and the information 
about the universe of chemical compounds and reactions 
("compound"/"glycan"/"reaction" databases). 
 
Microarray: an orderly arrangement of microscopic elements on a planar 
surface that allows the specific binding of genes or gene products. 
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Mismatch (MM): a 25-mer oligonucleotide designed to be complementary to a 
reference sequence except for a single, homomeric base change at the 13th position. 
Mismatch probes serve as specificity controls when compared to their corresponding 
Perfect Match probe. 
 
Nonparametric test: a statistical test without the assumption of a particular 
distribution of the data, also known as a distribution-free test. 
 
Normalization: a procedure that adjusts an average value of an experimental 
array equal to that of the baseline array so that they can be compared. 
 
Online Mendelian Inheritance in ManTM (OMIM): a catalog of human genes 
and genetic disorders authored and edited by Dr. Victor A. McKusick and his 
colleagues at Johns Hopkins and elsewhere, and developed for the World Wide Web 
by the NCBI. The database contains textual information and references. It also 
contains copious links to MEDLINE and sequence records in the Entrez system, and 
links to additional related resources at NCBI and elsewhere. 
 
Parametric test: a statistical test that assumes that the data sampled was 
from a population that follows a Gaussian or normal distribution. 
 
Pearson correlation test: a measure of the strength of the linear relationship 
between two variables, using the mean of the data. 
 
Perfect match (PM): a 25-mer oligonucleotide designed to be complementary 
to a reference sequence. 
 
Permutation test: a special case of randomization tests, i.e. tests that use 
randomly generated numbers for statistical inference. Randomization tests differ from 
parametric tests in many aspects, e. g. there is no requirement to have random 
samples from one or more populations, there is no need to assume anything about 
normality or variance equality, the null hypothesis has nothing to do with parameters, 
and the test statistic performed is not compared to tabled distributions but to the 
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results obtained when the data across the groups are repeatedly randomized (the 
corresponding statistic for each randomization is then calculated).  
 
Probe cell: a single square-shaped feature on an array containing probes with 
a unique sequence. 
 
Probe pair: two probe cells, designed as a Perfect Match (PM) and its 
corresponding Mismatch (MM). 
 
Probe set: two probe cells, designed as a Perfect Match (PM) and its 
corresponding Mismatch (MM). 
 
Probe: the molecule in solution that reacts with the target on the microarray 
slide. 
 
Reference Sequence (RefSeq): a collection that aims to provide a 
comprehensive, integrated, non-redundant set of sequences, including genomic 
DNA, RNA, and protein products, for major research organisms. 
 
Signal: a measure of the relative abundance of a transcript. 
 
Signal threshold approach: in this approach, a signal threshold is 
determined and genes whose signal is under this threshold are excluded; those low 
signal intensities that are near to the background levels increase variability or impair 
reproducibility of the measured ratios between control and experimental samples. 
 
Spearman correlation test: a measure of the strength of the linear 
relationship between two variables, using the mean of the ranks of the data, i.e. the 
lowest measurement becomes 1, the second lowest 2, and so forth. 
 
Stable gene/sample cluster (in CTWC):  a cluster that is statistically 
significant according to criteria described by Getz et al., 2002. 
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Target: the molecule attached to a microarray substrate that reacts with the 
free probe in the solution. 
 
Temperature parameter T (in CTWC): a tunable parameter that controls the 
resolution of the performed clustering. One starts at T=0, with a single cluster that 
contains all the objects. As T increases, phase transitions take place, and this cluster 
breaks into several subclusters that reflect the structure of the data. Clusters keep 
breaking up as T is further increased, until at high enough values of T each object 
forms its own cluster. 
 
T-test method: any statistical hypothesis test in which the test statistic has a 
Student's t-distribution if the null hypothesis is true. Student's distribution is a 
probability distribution that arises in the problem of estimating the mean of a normally 
distributed population when the sample size is small. The null hypothesis of a t-test 
always proposes that the two groups do not differ significatively, while the hypothesis 
of a t-test always proposes that there is a difference. 
 
Unigene: an experimental system for automatically partitioning GenBank 
sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster 
contains sequences that represent a unique gene, as well as related information 
such as the tissue types in which the gene has been expressed and map location. 
 
Wilcoxon-Mann-Whitney test: a nonparametric test appropriate to the case 
of two independent samples of observations that are measured at least at an ordinal 
level, i.e. we can at least say, of any two observations, which is the greater. The test 
assesses whether the degree of overlap between the two observed distributions is 
less than would be expected by chance, on the null hypothesis that the two samples 
are drawn from a single population. 
 
 
This glossary is based on information provided by Affymetrix, Wikipedia and 
NCBI websites. 
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1. Clinical characteristics of ALS 
1.1. General description 
 
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disorder 
of the motoneuronal system occuring in adult life. It was first described in 1869 by the 
french neurologist Jean-Martin Charcot (Charcot, 1874), who named it according to 
the clinical picture (muscle wasting = "amyotrophy") and the pathological findings 
(hardening of at least one side of the spinal cord = "lateral sclerosis"). Lou Gehrig 
brought first international attention to the disease in 1939 when he abruptly retired 
from baseball after being diagnosed with ALS. 
ALS affects motor neurons that reach from the brain to the spinal cord and 
from the spinal cord to the muscles throughout the body (Fig. 1). As motor neurons 
degenerate, they can no longer send impulses to the muscle fibers that normally 
result in muscle movement, so that the ability of the brain to initiate and control 
muscle movement is lost. For the vast majority of patients, their minds remain 
unaffected. While there is not a cure today that halts or reverses ALS, there is one 
Food and Drug Administration approved drug, riluzole (Rilutek®), that modestly slows 
the progression of ALS. 
 
1.2. Epidemiology 
 
The incidence of ALS has been estimated as around 1.5-2 per 100,000 per 
year (3-5 for multiple sclerosis (MS)), with a tendency toward an increasing incidence 
reported (Lilienfeld et al., 1989). Prevalence studies showed that up to 25,000 
Western Europeans suffer from ALS at any given time. Most people who develop 
ALS are between the ages of 40 and 70, with an average age of 58 (Li et al., 1990) at 
the time of diagnosis. However, cases of the disease do occur in persons in their 
twenties and thirties. The incidence of ALS seems to increase with advancing age 
(Juergens et al., 1980). 
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Fig. 1. Hierarchical organization of the motor system. 
The motor system has three levels of control: the spinal cord, the brain stem and the 
forebrain. The motor areas of the cerebral cortex can influence the spinal cord either 
directly or through the brain stem. All three levels of the motor system receive 
sensory inputs and are also under influence of the basal ganglia and the cerebellum.  
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Geographical differences in incidence have not been reported for ALS, with 
the exception of high-incidence foci in Asia and Oceania, in three Western Pacific 
population groups. These included the Chamorro people in Mariana Islands (Guam 
and Rota) (Reed et al., 1975; Reed & Brody, 1975), the Auyu and Jakai people of 
West New Guinea (Gajdusek & Salazar, 1982) and the Japanese residents of the Kii 
peninsula (Honshu island) (Kusui, 1962). The declining annual incidence (Garruto et 
al., 1985) coupled with the absence of demonstrable heritable or transmissible 
factors (Figlewicz et al., 1994) had led to focus the search for the cause of these high 
incidences on nontransmissible environmental factors. Among them, heavy use of 
certain toxic plants, notably cycads, has been proposed (Spencer et al., 1987), as 
well as secondary hyperparathyroidism, resulting from low environmental calcium 
and magnesium, and leading to abnormal deposition of calcium and aluminum in the 
central nervous system (CNS) (Garruto et al., 1985). 
Research studies investigating risk factors that may be associated with ALS 
proposed smoking, trauma, physical activity, exposure to lead, residence in rural 
areas and alcohol consumption being a probable risk factor for ALS (Armon 2003 for 
review). More work is needed to conclusively determine what environmental factors 
contribute to developing ALS. In contrast, variations in several genes relevant to 
motor neuron biology have been considered as possible modifying or risk factors for 
ALS. One example is the survival motor neuron (SMN) gene. Deficiency of the 
telomeric but not the centromeric copy of SMN gene causes recessively inherited 
spinal muscular atrophy. Detailed analyses of SMN genes in ALS documented that 
some variants in SMN seem to modify clinical parameters in sporadic ALS cases 
(Jackson et al., 1996; Parboosingh et al., 1999; Moulard et al., 1998; Corcia et al., 
2002). Polymorphisms or variants in other genes have also been considered as risk 
factors for ALS, including apolipoprotein E (Mui et al., 1995; al-Chalabi et al., 1996; 
Moulard et al., 1996; Smith et al., 1996), ciliary neurotrophic factor (Takahashi et al., 
1994; Takahashi, 1995; Orrell et al., 1995; Masu et al., 1993; Al-Chalabi et al., 2003), 
and the astrocytic glutamate transporter EAAT2/GLT1 (Lin et al., 1998; Trotti et al., 
1999). Recently, the possibility of a genetic predisposition in ALS was highlighted by 
a report of a high rate of constitutional chromosomal aberrations (5.9% vs 0.5-0.1% 
in the general population) (Meyer et al., 2003). 
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1.3. Clinical presentation and course 
 
The clinical hallmark of ALS is the coexistence of muscle atrophy, weakness, 
fasciculations, and cramps, together with hyperactive or inappropriately brisk deep 
tendon reflexes, pyramidal tract signs, and increased muscle tone (Table 1). Muscle 
cramps are often already present before other symptoms develop. Most patients 
present with asymmetrical, distal weakness of the arm or leg (Norris et al., 1993). 
Bulbar onset with slurred speech (dysarthria) and/or difficulty in swallowing 
(dysphagia) occurs in 20-30% of all cases, particularly in older females, more than 
50% of them presenting bulbar symptoms (Li et al., 1990). 
The symptoms usually progress first in the affected extremity, then gradually 
spread to adjacent muscle groups, with a remarkable variability in the rate of disease 
progression (Appel et al., 1987). Average disease duration is in the range of 3-4 
years, with 10% of patients surviving more than 10 years (Mulder & Howard, 1976) 
and some cases surviving over several decades (Grohme et al., 2001). Respiratory 
weakness due to high cervical and thoracic spinal cord involvement is the most 
common cause of death in ALS. 
There is usually no clinical involvement of parts of the CNS other than the 
motor pathways. Sensation, bladder, bowel and eye functions remain intact, and 
intellectual function together with personality are usually preserved, with only 2-3% of 
patients showing an associated dementia. 
 
1.4. ALS diversity 
 
Multiple clinical variants of ALS are now recognized which are associated with 
a spectrum of clinical outcomes from aggressive to rather indolent. Three major types 
of ALS are generally accepted. 
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Direct symptoms Indirect symptoms Absent symptoms
Motor weakness Psychic disturbances Sensation troubles
Amyotrophy Sleep disturbances Extraocular muscles paralysis
Fasciculations Constipation Incontinence
Muscle cramps Drooling Dementia
Spasticity Thick mucous secretions
Dysarthria Symptoms of chronic hypoventilation
Dysphagia Pain
Dyspnea
Pathologic laughing & crying
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Symptoms due to ALS 
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1.4.1. The Western Pacific type 
 
Often associated with dementia and a Parkinson's syndrome, this ALS form 
was observed in Guam and the Trust Territories of the Pacific in the 1950's (Brody et 
al., 1975), with a remarkable concentration since approximately 1 in 10 Guamanian 
deaths over age 25 was from ALS. 
 
1.4.2. The classical sporadic form 
 
Sporadic ALS (SALS) accounts for 90 to 95% of all cases. For these patients, 
there is no previous family history of this disorder. What is not clear is what factors 
contribute to the causation of this form. Although the cause may not be genetic, some 
mutations are thought to at least contribute to the pathogenesis of sporadic ALS, 
including deletions in the heavy neurofilament subunit tail (Al-Chalabi et al., 1999) 
and mutations of mitochondrial DNA (Vielhaber et al., 2000). 
 
1.4.3. The familial type 
 
Familial ALS (FALS) accounts for a very small number of patients with 5 to 
10% of all cases. Most of them show an autosomal dominant inheritance pattern. In 
those families, there is a 50% chance each offspring will inherit the gene mutation 
and may develop the disease. To date, nine loci have been associated with FALS 
and mutations in at least four genes have been found to be associated with this 
disease. 
 
Als1: a major breakthrough in deciphering the molecular mechanisms 
underlying ALS was provided by the observation that mutations in the gene encoding 
for the antioxidant enzyme Cu,Zn superoxide dismutase (SOD1) are carried by one-
fifth of FALS patients (Rosen, 1993). More than 100 mutations in this gene have 
been found in familial and sporadic cases of ALS (http://www.alsod.org). They are 
distributed among all five exons of the gene and result in the alteration of amino 
acids scattered throughout the SOD1 structure (Fig. 2).  
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Als2: als2 or alsin mutations cause an autosomal recessive form of juvenile 
ALS and have been mapped to chromosome 2q33 (Hadano et al., 2001; Yang et al., 
2001). Alsin long form belongs to the family of the guanine nucleotide exchanging 
factor for small GTPases. 
 
Als4: mutations in this gene are associated with a rare juvenile autosomal 
dominant disorder with slow progression, pyramidal signs, and severe muscle 
wasting (Rabin et al., 1999). This gene encodes a novel DNA/RNA helicase (Chen et 
al., 2004). 
 
Als8: a missense mutation in this gene causes an autosomal dominant slowly 
progressive disorder characterized by fasciculation, cramps, and postural tremor. 
This gene encodes the vesicle-associated membrane protein/synaptobrevin-
associated membrane protein B, an intracellular membrane protein that can 
associate with microtubules and that may have a function in membrane transport 
(Nishimura et al., 2004). 
 
The clinical expression of sporadic and familial ALS is very similar, although 
the age of onset is often lower for FALS (Camu et al., 1999), and more men are 
affected by SALS than women (ratio men/women for SALS  1.7/1 vs 1/1 for FALS). 
Thus, there is justified hope that insights gained from the study of the mechanisms 
leading to motor neuron degeneration from SOD1 mutation may also be relevant for 
SALS. 
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Fig. 2. SOD1 protein is a homodimer (From Beckman et al., 2001). 
The sidechains of mutated amino acids are shown in light blue and on the backbone 
as dark blue. The majority of the mutations are clustered on the top and bottom of 
the  barrel, in the dimer interface or along one of the loops that forms part of the Zn-
binding pocket. A major part of the C-terminal region shown in purple can be entirely 
deleted in a few individuals. Mutations Gly85Arg and Gly93Ala are indicated by 
arrows. 
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1.5. Diagnosis 
 
1.5.1. Clinical diagnosis 
 
The full-blown picture of classical ALS is difficult to misdiagnose, but diagnosis 
may be difficult at early stages when the patients complain of only unilateral, mostly 
distal weakness and wasting. Essentially, the diagnosis of ALS is a clinical one, 
based on criteria established on the basis of international expert consensus (Brooks, 
1994) and revised during a consensus conference held at Airlie House, Virginia 
(Brooks et al., 1998). These so-called El Escorial criteria (Table 2) reflect a 
consensus agreement concerning those features that imply certainty regarding the 
diagnosis ("definite ALS"), or degrees of uncertainty ("probable ALS"). The diagnosis 
of ALS requires the presence of both upper and lower motor neuron signs, with a 
progression of symptoms and signs over time. Initially devised for research, 
especially for clinical trials of potential therapies in the disease, the El Escorial criteria 
have shown some limits for accurate everyday clinical diagnosis. First, sensitivity and 
specificity of these criteria in relation to autopsy-confirmed experience has not been 
tested. Second, these definitions of different levels of diagnostic certainty do not 
indicate neither severity of disease nor rate of progression. Indeed, it is recognized 
that ALS progresses at different rates and in different ways in individual patients. 
Third, these criteria were concerned principally with defining classical Charcot's ALS, 
the most common form of the disease. Indeed, the issue of the relationships of 
classical Charcot's ALS syndrome with other clinical forms of the motor neuron 
disease syndrome, especially progressive muscular atrophy, progressive bulbar 
palpsy and primary lateral sclerosis, is not fully addressed. 
Identification of upper motor neuron affection is essentially based on clinical 
evidences, including brisk deep tendon reflexes (Hoffmann or Babinski signs) and 
spasticity. Structural magnetic resonance imaging (MRI) has proved to be useful in 
the visualisation of corticospinal tract abnormalities in ALS patients (Cheung et al.,  
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Main features
UMN signs pathologic spread of reflexes, clonus...
LMN signs weakness, atrophy, fasciculations
Progression
Diagnostic categories
Definite ALS UMN plus LMN signs in three regions
Probable ALS UMN plus LMN signs in at least two regions, with UMN signs rostral to LMN signs
Probabe ALS
Laboratory supported
UMN and LMN signs in one region,
or UMN signs in one region and LMN signs defined by EMG criteria in at least two limbs
Possible ALS
UMN plus LMN signs in one region,
or UMN signs in two or three regions,
or LMN signs in one region rostral to UMN signs
Absence of
Sensory signs
Autonomic dysfunction
Sphincter disturbance
Parkinsonism
Alzheimer-type dementia
ALS "mimic" syndromes
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Revised El Escorial criteria 
 
 
 
 
 
 
 
 
 
UMN: upper motor neurons. LMN: lower motor neurons. EMG: electromyography. 
Regions are defined as bulbar, cervical, thoracic, and lumbosacral. 
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1995; Mirowitz et al., 1989). Since these changes are non-specific and cannot be 
readily quantified, MRI essentially serves the purpose of ruling out other causes of 
the syndrome. However, proton magnetic resonance spectroscopy (MRS), which 
enables the investigation of metabolic changes in vivo, has been widely applied in 
ALS. Using MRS, different metabolites can be detected in the motor cortex and 
brainstem, including the neuronal marker N-acetyl aspartate (NAA), creatine / 
phosphocreatine, choline, myo-inositol, and glutamine / glutamate. The NAA signal 
has been shown to be decreased both in the motor area and in the brainstem in ALS, 
such a decrease being dependant on time and progression (Pioro et al., 1994; Block 
et al., 1998; Cwik et al., 1998). Quantification of NAA may therefore allow the 
assessment of disease progression but less likely contributes to early diagnosis in 
ALS, due to unresolved issues in the application of MRS including low sensitivity with 
substantial overlap between ALS patients and healthy controls, and multiple data 
acquisition techniques clearly limiting comparison between published studies. 
Positron emission tomography (PET) is another imaging tool to examine metabolic 
changes in vivo. This technique has been applied to ALS, using 2-18F-2-deoxy-D-
glucose (FDG) (Dalakas et al., 1987; Hatazawa et al., 1988) and 11C-flumazenil, a 
GABAA ligand (Lloyd et al., 2000), but further studies on sensitivity and specificity of 
these methods are necessary to establish 11C-flumazenil or FDG PET as a suitable 
diagnostic or progression marker. 
Lower motor neuron affection is clinically associated with progressive motor 
weakness, amyotrophy, fasciculations and muscle cramps. In addition to clinical 
examination, electrodiagnostic (EDX) techniques have been used in the evaluation of 
patients with clinically suspected ALS for nearly 50 years (Huddleston et al., 1950; 
Marinacci, 1955). The utility of the EDX examination in the assessment of patients 
with ALS was firmly established by Lambert (Lambert & Mulder, 1957), who listed a 
combination of four EDX findings that he considered highly supportive of the clinical 
diagnosis of ALS : two of these concerned the nerve conduction studies, and other 
two the needle electrode examination (Table 3). New EDX criteria were formulated by 
the El Escorial group, but they contain several flaws, which limit their use by 
electrodiagnostic physicians (Wilbourn, 1998). 
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Nerve conduction studies Needle electrode examination
1. Normal sensory NCS
3. Fibrillation and fasciculation potentials in muscles
of the upper and lower extremities or in the muscles
of the extremities and the head
2. Motor NCS CVs:
* normal when recording from relatively unaffected muscles
* not less than 70% of the age-based average normal value
when recording from severily affected muscles
4. MUPs reduced in number and increased in duration and amplitude
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. The Lambert criteria for the electrophysiological confirmation of ALS 
(From Wilbourn, 1998) 
 
 
 
 
 
NCS: nerve conduction studies. CVs: conduction velocities. MUPs: motor unit 
potentials. 
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1.5.2. Differential diagnosis 
 
Additional investigations may be required at early stages to exclude treatable 
diseases, and several diseases must be taken into consideration in the differential 
diagnosis of early ALS (Table 4). Among them, immune disorders (inclusion body 
myositis), infections (Prion disease), metabolic disorders (hyperthyroidism) and other 
neurological disorders (motor neuropathy, myopathic syndromes) may mimic ALS. 
There is no consensus about the appropriate range of laboratory tests to be ordered 
in making differential diagnosis of ALS (Table 5). They include cerebral spinal fluid 
(CSF) examination (the protein content of which seems to be related to lymphoma), 
bone marrow biopsy (reserved for patients with clinical suspicion of 
lymphoproliferative disease), quantitative electromyography (to avoid erroneous 
"neurogenic" patterns) and muscle biopsy (to exclude inclusion body myositis). 
 
1.5.3. Familial ALS diagnosis 
 
Diagnosis  can be achieved by genetic techniques in patients with familial ALS 
and mutations in the gene encoding for SOD1. In families with known SOD1 
mutations, mutational screening in persons at risk has the potential to detect 
preclinical cases and therefore be considered as a true diagnostic marker with high 
sensitivity and specificity. However, more and more mutations in the SOD1 gene are 
identified and several genes leading to ALS or predisposing to the disease are 
progressively discovered. The rarity of these families argues against a major impact 
of the corresponding gene product as a diagnostic marker. Moreover, a particular 
ethical dilemna is raised by the availability of these genetic markers. Should these 
family members be treated with riluzole prior to the expression of the ALS 
phenotype? Since the potential protective role of riluzole and its safety in this 
situation is unverified, it needs to be made clear to individuals at risk that the role of 
this and other treatments is at present undetermined. 
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ALS-mimic disorders
Cervical spondylotic myelopathy 
Benign fasciculation 
Primary lateral sclerosis and other forms of spastic paraparesis
Hexosaminidase deficiency
Spinobulbar muscular atrophy (Kennedy disease)
Monomelic spinal muscular atrophy (Hirayama syndrome)
Radiotherapy–myelopathy, neuronopathy, and neuropathy
Carpal tunnel syndrome
Inclusion body myositis
Hyperthyroidism
Polyglucosan body disease
Motor neuropathy neuropathy
Paraneoplastic motor neuron diseases
Monoclonal gammopathy
Lymphoproliferative disease
Breast cancer
Renal carcinoma
Multisystem disease: dementia, parkinsonism, cerebellar syndromes
AIDS, poliovirus, syphilis, Lyme disease, Creutzfeldt-Jakob disease
 
 
 
 
 
 
 
 
 
 
 
 
 
              Table 4. Conditions misdiagnosed as ALS (From Rowland 1998) 
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Aim Laboratory test
General health survey Blood counts, erythrocyte sedimentation rate; urinalysis; serological test for syphilis; chest film
Confirm diagnosis ALS EMG to show denervation in three limbs, tongue
Exclude unlikely causes MRI of brain, cervical spinal cord
Lyme antibodies
Blood and urine for heavy metals
Exclude inclusion body myositis Quantitative electromyography; muscle biopsy for rimmed vacuoles, amyloid stains
Exclude motor neuropathy Peripheral nerve conduction studies in all patients, with or without upper motor neuron signs
Motor nerve biopsy if no upper motor neuron signs
Exclude common carcinomas Rectal and prostate examination
Prostate specific antigen (men)
Breast examination and mammogram (women)
Bronchoscopy, biopsy any lesion found in chest film
Possible lymphoproliferative disease Serum protein immunofixation electrophoresis; quantitative immunoglobulins; Anti-MAG, anti-GM1; anti-Hu
Bone marrow biopsy if monoclonal protein found; other biopsy if lymphoma found
CSF examination
Possible familial ALS, Kennedy syndrome DNA analysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Laboratory tests in the diagnosis of ALS (From Rowland, 1998) 
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1.5.4. Early diagnosis and diagnostic delay 
 
With the introduction of riluzole and other therapeutical molecules in 
development or undergoing clinical trials, early diagnosis is increasingly important. A 
number of rationales supports the idea of early neuroprotective treatment (Cashman, 
1999; Riviere et al., 1998). However, the strategy of early treatment can be debated 
since effects of current therapeutic regimens are moderate (Ludolph & Riepe, 1999). 
Nevertheless, experimental data obtained in transgenic animal models for ALS and 
Huntington's disease clearly show that early preclinical pathogenesis can be 
dramatically influenced by therapeutic interventions (Kong & Xu, 1998; Bates, 2000; 
Yamamoto et al., 2000). Moreover, early diagnosis applies not only to early treatment 
having more impact on the disease and hence on quality of life of the patient, but 
extends to providing greater scope for inclusion in clinical trials (Swash, 1998). In 
addition, the psychological interests of people with ALS and their families are best 
served by a diagnostic process which is efficient, direct, clear and unambiguous 
(Johnston et al., 1996). 
Despite the introduction of riluzole therapy, the average time taken from 
symptom onset to ALS diagnosis seems to show no sign of improving. An initial 
incorrect diagnosis, refusal to consider the diagnosis when it was suggested by the 
informed patient, failure to consider a neurological cause for the patient's symptoms, 
and failure to make early referral to a neurologist may be among the major factors 
leading to delayed diagnosis (Househam & Swash, 2000). Consequently, there is a 
need of diagnostic markers able to screen phenotypically patients in early or 
preclinical disease stages. At present, there is only a single sensitive and specific 
marker for the diagnosis of ALS, the presence of mutations in the SOD1 gene. 
Otherwise, sensitive and specific diagnostic imaging, biochemical or genetic markers 
do not exist in ALS (Househam & Swash, 2000). 
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1.6. Measurements of disease progression 
 
It is possible to determine motor neuron death and dysfunction in ALS directly. 
Quantitative techniques exist for the evaluation of lower motor neuron survival based 
on motor unit number estimation (Dantes & McComas, 1991). However, these 
techniques are cumbersome, painful, and are not readily applicable to more than one 
muscle per patient. Measures of upper motor neuron integrity are also bedeviled by a 
host of problems. Cortical magnetic stimulation has proved to be useful in the 
detection of impaired integrity of descending corticomotor neurons in ALS patients 
(Eisen et al., 1996; Claus et al., 1995), but with limited sensitivity. Imaging techniques 
has also been used, including MRI (Cheung et al., 1995; Mirowitz et al., 1989; 
Segawa, 1993; Udaka et al., 1992; Yagishita, 1995; Oba et al., 1993), PET (Kew et 
al., 1994) or single photon emission tomography (SPECT) (Abe et al., 1993). 
However, structural changes emerge late during the disease progression and are 
difficult to quantify, and both PET and SPECT are invasive techniques that require 
exposure to radioactive isotopes. The sensitivity and variability of these measures 
within a patient group make imaging techniques unsuitable for determination of 
disease progression in clinical trials. 
Other indirect indicators of motor neuron degeneration have been used, 
including assays of muscle strength. Manual muscle testing (MMT) (Brooke et al., 
1983; Medical Research Council, 1976) (Fig. 3) and maximal voluntary isometric 
contraction (MVIC) (Miller et al., 1999a; Andres et al., 1986; Andres et al., 1988; The 
National Isometric Muscle Strength (NIMS) Database Consortium, 1996) (Fig. 4) 
megascores have been used in recent clinical trials to assess treatment effect on 
strength.  MMT may offer an advantage given the large number of muscles that can 
be sampled and the difference in cost, time and equipment required. Compared to 
MMT, MVIC is limited by the number of muscles sampled, the restrictions of time and 
patient fatigue associated with the technique, and the requirement of special 
equipment and technical expertise. Which has the best reproducibility and sensitivity 
is still debated (Aitkens et al., 1989; Andersen & Jakobsen, 1997; Hoagland et al.,  
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Fig. 3. Manual muscle testing (MMT) of shoulder abductors. 
MMT is a scored neurologic examination for assessment of muscle strength. The 
scale is numerical, with scores between 0 and 10, and is based on the examination of 
34 muscles: neck flexors and extensors; shoulder abductors and external rotators; 
elbow flexors and extensors; wrist extensors and flexors; abductor pollicis brevis; 
flexor digiti minimi; hip flexors, extensors, and abductors; knee extensors and flexors; 
ankle dorsiflexors; plantar flexors; and extensor hallucis longus. Each muscle is 
scored from 0 to 5, with 0 representing paralysis and 5 normal strength and then 
converted to a 10-point scale. The final MMT score is the mean of the scores of all 34 
muscles. 
During MMT of shoulder abductors (shown in b), the test is begun by first stabilizing 
the patient with the arm abducted to approximately 90 degrees with the palm facing 
down, the subject's contralateral hand grabbing the side of the table to help stabilize. 
The examiner instructs the patient to resist as hard as possible and then gradually 
applies a downward force to depress the limb. The hand-held dynamometer
(example shown in a) records the peak force during the movement.  
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Fig. 4. Maximal voluntary isometric contraction (MVIC). 
MVIC may be measured quantitatively in multiple muscles, each one tested by a 
fixed load cell tensiometer interfaced with a computer for data acquisition and 
storage. MVIC may be measured in multiple muscle groups, including shoulder 
extension, elbow flexion, grip strength, hip flexion, knee extension, ankle 
dorsiflexion… Data are generally normalized, summed, and averaged to yield a 
megascore, which is then processed for data interpretation. 
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1997; Great Lakes ALS Study Group, 2003; Visser et al., 2003) but both techniques 
lack interobserver reproducibilty, have to be performed by trained physical therapists 
and no consensus remains on which muscles and how many should be tested. 
Respiratory muscles activity is also measured by numerous tests. Forced vital 
capacity (total amount of air exhaled during a forced expiratory volume test, 
measured during spirometry) is commonly used but can remain normal despite 
substantial inspiratory muscle weakness. Maximal pressures measured at the mouth 
are useful for excluding weakness if they are normal but are difficult to interpret if 
abnormal. Invasive testing, such as measurement of transdiaphragmatic pressure, 
provides an accurate measure of inspiratory strength but is not readily available and 
is not practical for serial measures. 
Disability and illness impact scales also provide indirect information about 
motor neuron degeneration. They include Norris ALS Scale (Norris et al., 1974), 
Appel ALS Scale (Appel et al., 1987), ALS Severity Scale (ALSSS) (Hillel et al., 
1989), the sickness impact profile (Lai et al., 1997) and the ALS Functional Rating 
Scale (ALSFRS) (Table 6). ALSFRS is a dysfunction scale used in assessing the 
activities of daily living of patients with ALS. It was originally developed during the 
Regeneron CNTF phase I-II trials (The ALS CNTF treatment study (ACTS) phase I-II 
Study Group, 1996), based on the Unified Parkinson's Disease Rating Scale (Fahn & 
Elton, 1987) and the ALSSS, and revised by the brain-derived neurotrophic factor 
ALS Study Group Phase III (Cedarbaum et al., 1999). Although ALSFRS is a 
commonly accepted standard for monitoring disease progression used in clinical 
trials and in the treatment of ALS patients, much of what this scale is assessing are 
downstream functional effects of the disease, largely influenced by factors other than 
neuronal death, including individual motivation, family support, and financial 
ressources. Moreover, its sensitivity, especially at the early stages of the disease, 
remains low. 
Unfortunately, all such scales, including survival itself, are only related 
indirectly to the true biological lesion responsible for disease progression, namely the 
death and dysfunction of motor neurons. Moreover, none of these methods 
discriminate between upper and lower motor neuron involvement. Finally, all indirect  
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      Function  Performance Score
 (1) Speech  Normal speech processes 4
 Detectable speech disturbance 3
 Intelligible with repeating 2
 Speech combined with nonvocal communication 1
 Loss of useful speech 0
 (2) Salivation  Normal 4
 Slight but definite excess of saliva in mouth; may have nighttime drooling 3
 Moderately excessive saliva; may have minimal drooling 2
 Marked excess of saliva with some drooling 1
 Marked drooling; requires constant tissue or handkerchief 0
 (3) Swallowing  Normal eating habits 4
 Early eating problems — occasional choking 3
 Dietary consistency changes 2
 Needs supplemental tube feeding 1
 NPO (exclusively parenteral or enteral feeding) 0
 (4) Handwriting  Normal 4
 Slow or sloppy: all words are legible 3
 Not all words are legible 2
 Able to grip pen but unable to write 1
 Unable to grip pen 0
 (5a) Cutting food and handling utensils  Normal 4
 (patients without gastrostomy )?  Somewhat slow and clumsy, but no help needed 3
 Can cut most foods, although clumsy and slow; some help needed 2
 Food must be cut by someone, but can still feed slowly 1
 Needs to be fed 0
 (5b) Cutting food and handling utensils  Normal 4
 (alternate scale for patients with gastrostomy )?  Clumsy but able to perform all manipulations independently 3
 Some help needed with closures and fasteners 2
 Provides minimal assistance to caregiver 1
 Unable to perform any aspect of task 0
 (6) Dressing and hygiene  Normal function 4
 Independent and complete self-care with effort or decreased efficiency 3
 Intermittent assistance or substitute methods 2
 Needs attendant for self-care 1
 Total dependence 0
 (7) Turning in bed and adjusting bed clothes  Normal 4
 Somewhat slow and clumsy, but no help needed 3
 Can turn alone or adjust sheets, but with great difficulty 2
 Can initiate, but not turn or adjust sheets alone 1
 Helpless 0
 (8) Walking  Normal 4
 Early ambulation difficulties 3
 Walks with assistance 2
 Nonambulatory functional movement 1
 No purposeful leg movement 0
 (9) Climbing stairs  Normal 4
 Slow 3
 Mild unsteadiness or fatigue 2
 Needs assistance 1
 Cannot do 0
 (10) Dyspnea (new )  None 4
 Occurs when walking 3
 Occurs with one or more of the following: eating, bathing, dressing (ADL) 2
 Occurs at rest, difficulty breathing when either sitting or lying 1
 Significant difficulty, considering using mechanical respiratory support 0
 (11) Orthopnea (new )  None 4
 Some difficulty sleeping at night due to shortness of breath,
does not routinely use more than two pillows 3
 Needs extra pillows in order to sleep (more than two) 2
 Can only sleep sitting up 1
 Unable to sleep 0
 (12) Respiratory insufficiency (new )  None 4
 Intermittent use of BiPAP 3
 Continuous use of BiPAP during the night 2
 Continuous use of BiPAP during the night and day 1
 Invasive mechanical ventilation by intubation or tracheostomy 0
ALSFRS = SUM(score for all 12 measures)
   Table. 6. The amyotrophic lateral sclerosis functional rating scale (ALSFRS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALSFRS is an instrument for evaluating the functional status of patients with ALS. It 
can be used to monitor functional change in a patient over time. The higher is the 
score, the more function is retained. 
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measurements of motor neuron integrity are subject to considerable variability, due to 
a variety of poorly controlled factors. From the perspective of clinical trials, adequate 
statistical power necessitates large numbers of patients observed over a long period 
of time, which makes proof of efficacy of a drug in ALS patients extremely expensive. 
The development of biological markers to measure disease progression and 
their implementation in clinical trials may therefore be a necessary step to reduce 
both the required sample size and trial periods (Kaye, 2000). Biomarkers which have 
been advanced as potential surrogate markers include increased concentration of 
glutamate in CSF (Shaw et al., 1995; Spreux-Varoquaux et al., 2002) or in plasma 
(Iwasaki et al., 1992), abnormal concentration of kynurenic acid in CSF and serum 
(Ilzecka et al., 2003), increased level of prostaglandin E2 in CSF and serum (Ilzecka, 
2003), elevated levels of creatine kinase in serum (Ilzecka & Stelmasiak, 2003a), 
decreased serum bilirubin concentration (Ilzecka & Stelmasiak, 2003b), increased 
serum levels of metalloproteinase-9 (Beuche et al., 2000) and transforming growth 
factor-1 (Houi et al., 2002). Elevated CSF or serum levels of markers of oxidative 
injury have been also proposed, including indices of DNA oxidative injury (Bogdanov 
et al., 2000), protein oxidation (Beal et al., 1997), and lipid peroxides (Smith et al., 
1998; Simpson et al., 2004). Markers of apoptosis either in serum (Ilzecka et al., 
2001; Sengun & Appel, 2003) or in blood (Poloni et al., 2000) have also been 
advanced. However, no relevant correlations with clinical features were found for 
these biomarkers. Therefore, there is a need to identify reliable and sensitive 
surrogate markers of the evolution of the disease. 
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2. Clinical management of ALS 
 
2.1. Preventive therapy 
 
Preventive therapy includes only relatives of SOD1-linked FALS patients. The 
availability of genetic testing for these families poses a dilemma : substances that are 
effective in the SOD1 transgenic mouse model (section 3.), such as creatine, riluzole, 
or vitamin E (Klivenyi et al., 1999; Gurney et al., 1996), may be potential preventive 
drugs for persons at risk for FALS but the uncertain benefits on human must be 
weighted against the burden of knowledge of their high-risk status as carriers of the 
mutation. 
 
2.2. ALS-specific therapies 
 
There is no satisfactory curative treatment for ALS. The antiglutamatergic 
agent riluzole has been estimated to prolong life by a few months in patients with 
ALS (Lacomblez et al., 1996). Around 10-15% of patients discontinue treatment 
because of side effects (asthenia, dizziness, gastrointestinal problems), and a few 
have to stop because of significant liver enzyme elevation. A Practice Advisory was 
issued summarizing the data on riluzole (Practice advisory on the treatment of 
amyotrophic lateral sclerosis with riluzole, 1997). A number of concerns about 
therapeutic effect persists: the lack of benefit observed in most secondary measures 
of efficacy, the quite modest prolongation of survival, and the relatively high cost of 
the drug. 
Creatine is a nonprescription dietary supplement that has been shown to 
prolong life of SOD1 transgenic mice for twice as long as riluzole in the same model 
(Klivenyi et al., 1999). Two clinical trials of creatine in ALS have been completed 
without demonstration of significant improvements in overall survival or a composite 
measure of muscle strength (Groeneveld et al., 2003; Shefner et al., 2004). 
Several attempts at finding a cure for ALS have failed so far, trophic factors 
being the most prominent example. However, there are ongoing trials of new 
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therapeutic agents, such as Ceftriaxone. There are also promising new drugs in the 
laboratory pipeline, such as vascular endothelial growth factor (VEGF) (Storkebaum 
et al., 2005; Azzouz et al., 2004)). In addition, recent findings guide researchers 
towards new therapies for the disease, such as gene therapy developments, stem 
cell research (Corti et al., 2004) or RNA silencing (Ralph et al., 2005). 
 
2.3. Palliative care 
 
Given the paucity of available curative options,  palliative care is the mainstay 
of clinical management in ALS. It is a multidisciplinary approach that starts with the 
way the diagnosis is communicated and goes all the way to bereavement counseling 
for relatives after the patient's death. A first attempt at establishing evidence-based 
guidelines for clinical management of ALS has been published (Miller et al., 1999b) 
but many questions in this field have not yet been addressed. 
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3. Mutant SOD1 transgenic mice 
 
The study of ALS has been hampered for a long time by the fact that no 
animal model was available. Studies of humans with ALS are complicated by the lack 
of genetic homogeneity or environmental uniformity. Moreover, possible early signs 
of disease that might appear prior to overt symptoms and could allow preemptive 
medical intervention are difficult to identify. A breakthrough in ALS was the discovery 
of a variety of mutations in the human SOD1 in about 20% of FALS cases (Rosen, 
1993). This enabled the development of novel experimental models corresponding to 
transgenic mice expressing mutant forms of SOD1. To date, seven mouse models 
transgenic for mutant SOD1 have been generated (Wong et al., 1995; Bruijn et al., 
1997; Ripps et al., 1995; Gurney et al., 1994; Friedlander et al., 1997; Dal Canto & 
Gurney, 1997; Dal Canto & Gurney, 1995) (Table 7). In mutant SOD1 mice, hind limb 
weakness appears as initial symptoms, followed by major symptoms such as 
progressive motor paralysis and neurogenic amyotrophy. These mice subsequently 
show disability of gait, eating and drinking, and die within some weeks. In our 
laboratory, we studied the SOD1 G86R mice (Ripps et al., 1995) (Fig. 5), that contain 
a transgene with the missense mutation Gly-86  Arg, a mutation already observed 
in the corresponding amino acid residue of some patients with FALS (position 85, 
Fig. 2) (Rosen, 1993; Deng et al., 1993). Mutant SOD1 transgenic mice have 
provided many valuable insights into the pathogenesis of ALS, both by identifying 
early events in the neurodegenerative process and by attempting preemptive 
therapy. 
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Mutation Line - transgene copy number SOD1 activity in CNS relative to control Onset (days old) Duration (days) Reference
hG37R 42 14.5 120 ND 12
9 9 150 ND 12
106 7.2 180 ND 12
29 7 210 ND 12
hG85R 148 1 240 7--14 13
mG86R M1 1 100 7 14, Fig. 5
hD90A Hetero Slightly increased 130 600 15
Homo Markedly increased ND ND 15
hG93A G1H/+ - 25 13 90 <60 18
G1L/+ - 18 11 130 <70 15.17
G5/G5 - 10 7 290 >110 18
hG93R ND ND 230 10--13 16
hI113T ND Slightly increased 330 slow X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Transgenic mice expressing mutant SOD1 (Adapted from Shibata, 
2001) 
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Fig. 5. The SOD1 G86R mouse is a model of ALS. 
Histological analysis of the motor system on sections of lumbar spinal cord, sciatic 
nerve, and corresponding gastrocnemius muscle from 75- and 105-day-old SOD1 
G86R mice. Sections were stained with toluidine blue. In 105-day-old mice tissues, 
note the decrease of motor neurons and the picnotic aspect of remaining perikarya 
(red arrows, first panel) in the lumbar spinal cord, the typical Wallerian degeneration 
of myelinated fibers in the sciatic nerve (yellow circles, second panel), and the 
muscle atrophy and degeneration (red arrows, third panel), compared to 75-day-old 
mice tissues. 
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4. Skeletal muscle in ALS 
 
4.1. Skeletal muscle is a potential tool in ALS monitoring and 
diagnosis 
 
Given the emergence of neuroprotective treatment strategies in ALS, there is 
a need to monitor ALS-modifying effects during clinical trials and to find ALS sensitive 
and specific markers for early diagnosis. Sections 1.5 and 1.6 of the introduction 
have shown that markers currently available are unsatisfactory, for lack either of 
sensitivity, specificity, reproducibility, safety, reliability, practicality, cheapness or 
quickness. Using skeletal muscle as a target to identify biological markers presents 
several advantages. Skeletal muscle is an easily accessible tissue by biopsy, needle 
biopsy is a little-invasive procedure (Fig. 6) and muscle biopsy is routinely performed 
for histopathological purposes. New technologies measuring gene expression such 
as quantitative polymerase chain reaction (QPCR) or microarrays needs little genetic 
material, may be rapidly applied to large number of subjects, and requires less and 
less specific equipment, technical expertise, cost and time. Moreover, these 
techniques provides quantitative, sensitive, reproducible and observer-independent 
data. Therefore, genetic regulations in ALS muscle that correlate with clinical 
parameters of the disease constitute potential markers of ALS progression. For 
diagnostic purposes, genes specifically regulated in ALS muscle constitute potential 
diagnostic markers of the disease. Finally, proteins coded by these regulated genes 
might be detected in biological fluids and consitute markers even cheaper and more 
suitable to perform serial examinations. 
 
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Muscle biopsy procedure. 
A muscle biopsy is a procedure involving the removal and examination of a piece of 
muscle tissue. It can usually be obtained while you are awake and the area being 
biopsied is numbed by local anesthesia. No fasting or other special preparation is 
usually necessary. In a needle biopsy procedure, a needle in inserted into the muscle 
and a small "plug" of tissue remains in the needle when it is removed from the 
muscle. During the biopsy, there is usually minimal or no discomfort. The anesthetic 
may burn or sting when injected before the area becomes numb. After the anesthetic 
wears off, the area may be sore for about a week. 
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4.2. Potential involvement of skeletal muscle in ALS etiology 
 
There is a general acceptance that ALS is a motorneuron disease. However, 
current theories are shifting from an exclusive motor neuron pathology to a focus on 
the interaction between motor neurons and other cell types. Indeed, targeted 
expression of mutant SOD1 either in motor neurons (Pramatarova et al., 2001; Lino 
et al., 2002) or in astrocytes (Gong et al., 2000) does not lead to an ALS-like 
phenotype, suggesting that these cell types may not be primarly involved in ALS 
pathogenesis. Moreover, SOD1 mutant neurons survive longer when surrounded by 
an environment having a high proportion of wild-type nonneuronal cells, supporting 
the view that the cellular background of motor neurons is a determining factor in the 
degeneration process caused by SOD1 mutations (Clement et al., 2003). Damaged 
nonneuronal cells and motor neurons, therefore, could act in concert to provoke the 
disease. Many studies focused on the role of astrocytes in the motor neuron loss in 
ALS (Barbeito et al., 2004), most likely due to their close interactions, astrocytes 
providing  structural, metabolic and trophic support to neurons, and actively 
participating in modulating neuronal excitability and neurotransmission. However, 
little is known about the influence exerted on motor neurons by other cells types, 
including skeletal muscle cells. 
Examination of muscle biopsy samples from ALS patients by electron 
miscroscopy revealed ultrastructural abnormalities of muscle mitochondria (Chung & 
Suh, 2002). These abnormal mitochondria are associated with mitochondrial 
dysfunctions in skeletal muscle of ALS patients (Siciliano et al., 2001; Vielhaber et 
al., 1999; Vielhaber et al., 2000; Wiedemann et al., 1998). These findings, together 
with many different metabolic alterations observed in the disease, have contributed to 
the emergence of the quite recent metabolic hypothesis in ALS pathogenesis  
[(Gonzalez de Aguilar et al., 2005) for review]. In this paradigm, failure in skeletal 
muscle, a metabolically important tissue, may constitute an additional driven force to 
increase motor neuron vulnerability. Interestingly, the hypothesis making the skeletal 
muscle an active player for initiating the development of ALS takes account of an 
essential characteristic of the disease, which is isolated involvement of the motor 
system. 
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Other data support primitive muscle involvment in ALS. Studies in G93A mice 
revealed an increase in SOD activity during progression of disease in muscles, but 
not in nervous tissue, associated with changes in mitochondria respiratory properties 
in oxidative muscle fibers (Leclerc et al., 2001). These findings suggest that oxidative 
stress due to SOD1 mutations could alter energy metabolism in FALS mice, thereby 
affecting primarily oxidative muscle of the limbs, independently of motor neuron loss. 
Besides, our recent results on SOD1 mice are strongly indicative of the early and 
long-lasting activation of a series of molecular effectors thought to act coordinately in 
preventing the increased oxidative stress in ALS muscle [Article 4]. Another study in 
G93A mice revealed by MRI a decrease in hindlimb muscle volume, before other 
overt pathology appeared. In line with these findings, many studies in G93A mice 
have demonstrated dysfunction of the neuromuscular junction long before the loss of 
motor neurons are reported. Whereas significant loss of motor neurons is not 
detected before 80-90 days in G93A mice (Chiu et al., 1995; Kennel et al., 1996), 
selective loss of fast-firing neuromuscular synapses as early as day 50 (Frey et al., 
2000), progressive loss of motor unit numbers begginning at day 40 (Kennel et al., 
1996), and 40% of end-plates denervation at day 47 (Fischer et al., 2004) have been 
reported. Moreover, autopsy of a patient with SALS demonstrated denervation and 
reinnervation changes in muscle but normal appearing motor neurons (Fischer et al., 
2004). Altogether, these observations imply that ALS is actually a "dying-back" motor 
neuropathy where distal axonal degeneration occurs early during the disease, before 
neuronal degeneration and onset of motor symptoms, at least in the widely studied 
G93A mice and in a human case. 
Skeletal muscle may be an important actor in this "dying-back" process, by 
controlling the terminal sprouting. Thus, local retrograde signaling does play a role in 
regulating nerve growth at the synapse, notably during development of the nervous 
system with cell adhesion molecules like N-CAM and N-cadherin or with soluble 
trophic factors like brain-derived neurotrophic factor and ciliary neurotrophic factor. 
Not only developping but adult muscle is a source of signals that influence neuron 
survival, axonal growth, and maintenance of synaptic connections (Funakoshi et al., 
1995). In accordance with this, overexpression of glial cell line-derived neurotrophic 
factor (GDNF) by muscle greatly increased the number of motor axons innervating 
neuromuscular junctions in neonatal mice (Nguyen et al., 1998). Most interestingly, 
muscle-restricted expression of a localized insulin like growth factor-1 (IGF-1) isoform 
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in G93A mice stabilized neuromuscular junctions, reduced inflammation in the spinal 
cord, and enhanced motor neuronal survival, delaying the onset and progression of 
the disease (Dobrowolny et al., 2005). Similarly, viral muscle delivery of GDNF 
(Acsadi et al., 2002; Wang et al., 2002b; Mohajeri et al., 1999; Manabe et al., 2002; 
Lu et al., 2003) or IGF-1 (Kaspar et al., 2003) can increase survival in G93A mice. A 
possible origin for a deleterious retrograde signaling could be metabolic alterations in 
skeletal muscle, which might contribute to an "undernourishment" of the most distal 
region of the axon. 
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Objectives and 
Organization of the Results
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ALS is emerging as a “multi-system” disease in which the alteration in both 
muscle, motor neuron and glia cells may act synergistically to induce the disease. 
Although skeletal muscle is quite an untested component in the motor 
neurodegenerative process in ALS, findings described in the introduction establish 
skeletal muscle as a promising primary target in ALS research. Indeed, skeletal 
muscle is of greatest interest both as a clinical tool in monitoring and diagnosing ALS 
patients, and as a primary actor in ALS pathogenesis. Therefore, the aim of the 
present PhD work was to explore gene expression modifications in ALS skeletal 
muscle in order to identify molecular markers of the disease. Two independent 
approaches were conducted in parallel using muscle as a starting point. First, our 
gene expression studies targeted two gene families, focusing on two proteins 
particulary relevant as molecular markers of ALS, named Nogo-A and UCP3, 
described respectively in chapter 1 and chapter 2 of the results. Second, we 
extensively explored the transcriptome of ALS muscle using a DNA microarray 
approach described in chapter 3. This systematic strategy enabled us to establish a 
molecular identity card of skeletal muscle affected by ALS and identify two groups of 
genes of particular interest from a clinical point of view. 
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1. Nogo-A is a potential marker of ALS 
 
1.1. Reticulon family 
 
Reticulons are a family of highly conserved proteins (Oertle et al., 2003b), 
which are ubiquitously expressed in vertebrates and have also been described in 
Drosophila melanogaster, Schizosaccharomyces pombe (Godoy et al., 1996) and 
Caenorhabditis elegans (Iwahashi et al., 2002). Initially described as specific for 
neural tissue (Wieczorek & Hughes, 1991; Kools et al., 1994) and markers for some 
types of lung cancer (Roebroek et al., 1993), these proteins were called 
neuroendocrine-specific proteins, owing to its neuroendocrine-specific expression. 
Due to their preferred intracellular localization in the endoplasmic reticulum (ER), 
they were renamed reticulons (RTNs) (van de Velde et al., 1994a). 
In mammals, four genes (rtn1, rtn2, rtn3 and nogo/rtn4) lead to the expression 
of multiple alternative transcripts (Fig. 7). They all share a homologous carboxyl 
terminus composed of ~200 amino acids and called the reticulon homolgy domain 
(RHD). RHD features two large hydrophobic regions, potentially corresponding to two 
transmembrane domains, and a ~66 amino acids loop in between. RTN1, 2 and 4 are 
expressed as multiple N-terminal isoforms that are generated by differential promoter 
usage or alternative splicing (Oertle et al., 2003a). Since RTN3 was the only RTN 
known to exist in only one isoform, bearing a very short N-terminal domain and the 
RHD (Hamada et al., 2002; Moreira et al., 1999), we analysed databases for potential 
new RTN3 isoforms [Article 1]. We described a revised genomic structure of mouse 
and human gene rtn3, which contain nine exons that may encode up to eight putative 
gene products. Only five of these variants were present at the mRNA and protein 
levels. 
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Fig. 7. Exon-intron structure of the four mammalian RTN genes (From Oertle, 
2003). 
Exons coding for the RHD are indicated in black, in gray those coding for the amino 
termini, and in white boxes the UTRs. Arrows indicate the translation start sites.
Numbers designate intron phasing. Exon sizes are matched according to the 
indicated line.  
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1.2. Functions of mammalian RTNs 
 
At present, little is known about the functions of RTNs [(Oertle & Schwab, 
2003) for review]. In the ER, RTN1-A forms aggregates with RTN1-B (Senden et al., 
1994a), but not with RTN1-C (Senden et al., 1996). Such a complex is thought to 
work as a pore-like structure but evidence supporting this notion is still lacking. 
Similarly, Nogo-A could also form a membrane channel or transporter by interacting 
with its isoform partners Nogo-B and Nogo-C (Dodd et al., 2005). RTNs do not only 
associate with the ER but also with other cellular constituents, including the plasma 
membrane and the Golgi apparatus (Chen et al., 2000; GrandPre et al., 2000). Thus, 
RTN1-C and RTN3 have been proposed to participate in the trafficking of proteins 
between the ER and the other membrane compartments (Steiner et al., 2004; 
Wakana et al., 2005). 
The presence of multiple putative SH3-domain-binding sites in the N-terminal 
region of Nogo (Oertle et al., 2003a) has suggested the occurrence of protein-protein 
interactions. Such interactions have been already reported, including RTN2 
interaction with the intermediate filaments in the Z-bands of muscle sarcomeres 
(Geisler et al., 1999), Nogo interaction in nervous tissue with ubiquinol-cytochrome c 
reductase core protein II and with NIMP (Nogo-interacting mitochondrial protein, a 
new mitochondrial protein) (Hu et al., 2002), as well as with alpha-tubulin and myelin 
basic protein (Taketomi et al., 2002), and RTN1-A and RTN1-B interaction with the 
AP-2 adaptator complex involved in endocytosis (Iwahashi & Hamada, 2003). These 
interactions may account for novel functions of RTNs. 
Several studies reported the implication of RTNs in apoptosis. RTN1-C and 
Nogo-B interact with the anti-apoptotic proteins Bcl-xL and Bcl-2 sequestring them 
from mitochondria to the ER and hence preventing their anti-apoptotic actions 
(Tagami et al., 2000). RTN1-C also interacts with the pro-apoptotic enzyme 
glucosylceramide synthase to modulate its catalytic activity (Di Sano et al., 2003). 
Upon cell death of cerebellar granule neurons, RTN3-A1, RTN3-A2 and RTN3-A4 
expression is repressed, probably through an apoptotic-dependent process [Article 
1]. Concerning Nogo-B, its pro-apoptotic function is still debated (Li et al., 2001; Qi et 
al., 2003; Tambe et al., 2004; Oertle et al., 2003c). In addition to apoptosis, growing 
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data endow RTNs with new roles in many different tissues, including vascular 
remodeling in endothelial and smooth muscle cells (Acevedo et al., 2004), response 
to hydrostatic pressure in chondrocytic cells (Sironen et al., 2004) and amyloid-beta 
metabolism modulation in human brain (He et al., 2004). 
Most of the existing literature on RTNs deals with the role of Nogo as a potent 
inhibitor of axonal growth and repair. Nogo-A, the longest Nogo isoform, was initially 
characterized as a myelin fraction protein recognized by a monoclonal antibody able 
to neutralize its growth-inhibitory activity (Caroni & Schwab, 1988). This growth cone 
collapse activity is presently known to occur mainly through the interaction of the 
Nogo-66 loop with a receptor complex, formed by a glycosyl phosphatidyl inositol-
anchored membrane receptor called NgR (Fournier et al., 2001), the low-affinity 
nerve growth factor receptor p75NTR (Wang et al., 2002a), and a nervous system-
specific transmembrane protein named LINGO-1 (Mi et al., 2004). In addition to this 
receptor complex, TROY, an orphan tumor necrosis factor receptor family member 
widely expressed in the nervous system, may also interact with NgR and LINGO-1 to 
mediate the inhibitory action of Nogo-A (Park et al., 2005; Shao et al., 2005). Neurite 
outgrowth inhibition is also supported by two additional Nogo-A-specific active 
fragments in the N-terminal region, named NiR-∆2 and NiG-∆20, which also prevent 
fibroblast spreading (Oertle et al., 2003d). Although acting via different neuronal 
binding sites, the actions of both Nogo-66 and NiG-∆20 converge at the Rho-
GTPases RhoA and Rac1 to inhibit neurite outgrowth (Schweigreiter et al., 2004). 
Most of Nogo-A is retained in the ER but it is also present at the cell membrane of 
oligodendrocytes (Nie et al., 2003). Therefore, it is assumed that the exposure of 
Nogo-A and NgR at the interface between neurons and oligodendrocytes is in part 
responsible for the failure of CNS regeneration. Although regeneration abilities of 
Nogo knockout mice are still debated (Simonen et al., 2003; Kim et al., 2003; Zheng 
et al., 2003), many studies, reporting both findings on Nogo/Nogo receptor 
distribution (Josephson et al., 2001; Huber et al., 2002; Buss et al., 2004; Al Halabiah 
et al., 2005), and functional findings (Emerick et al., 2003; Mingorance et al., 2004; 
Lee et al., 2004; Kim et al., 2004; Li et al., 2004), support Nogo as an important actor 
in the modulation of axonal pathfinding during development and in the adaptative 
response of the adult CNS to axonal injury. 
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1.3. RTNs as disease markers 
 
1.3.1. RTNs in cancer 
 
RTNs were initially described as markers of neural and neuroendocrine 
differentiation in normal and malignant cells. Thus, RTN1-A and RTN1-C are 
expressed in most of the small-cell lung carcinoma (SCLC) and carcinoids, whereas 
they are absent in non-SCLC tumors (except for non-SCLCs exhibiting 
neuroendocrine features that also show RTN1-A expression) (van de Velde et al., 
1994b; Senden et al., 1997b; Senden et al., 1994b). Serum autoantibodies to Nogo-A 
are a frequent finding in pilocytic astrocytoma patients (Michel et al., 1999). Similarly, 
overexpression of RTN3 was reported in astrocytoma tumor cells, as compared to 
non-cancerous brain tissue. Therefore, RTN antibodies might serve as novel markers 
for these cancerous diseases. 
 
1.3.2. RTNs in neurological diseases 
 
Despite the important role that RTNs seem to play in the nervous system, little 
is known about the implication of these proteins in neurological diseases. Reductions 
of RTN1-C levels have been reported in cortex from Down syndrome and Alzheimer's 
disease (AD) patients (Kim et al., 2000). RTN family members have been shown to 
bind -amyloid converting enzyme 1 (BACE-1), the type I transmembrane aspartyl 
protease reported to be the -secretase involved in AD. In vitro changes in RTN3 
expression markedly modulate BACE1 protease activity, suggesting that changes in 
RTN expression in the human brain are likely to affect cellular amyloid- and the 
formation of amyloid plaques involved in AD pathogenesis (He et al., 2004). 
Serum autoantibodies to Nogo-A are a frequent finding in MS, acute 
inflammatory and non-inflammatory neurological diseases (Reindl et al., 2003). High 
levels of Nogo-A mRNA were detected in frontal cerebral cortices from patients with 
schizophrenia (Novak et al., 2002). Increased expression of Nogo-A was also 
observed in hippocampal neurons of patients with temporal lobe epilepsy (Bandtlow 
et al., 2004) and in rat hippocampus in a kainic acid model of this disease (Meier et 
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al., 2003). According to these observations and those reporting the neuroprotective 
effect of Nogo-A vaccination on the lesioned spinal cord (Hauben et al., 2001; 
GrandPre et al., 2002), it was proposed that vaccination against Nogo-A was an 
interesting therapeutical approach for neurological diseases (Merkler et al., 2003). In 
this regard, targeting Nogo-A by active immunization supresses clinical and 
histological signs associated with experimental autoimmune encephalomyelitis, a 
model of MS (Karnezis et al., 2004). However, the type of recruited immune response 
may negatively influence the effects of this kind of therapeutical approach  (Fontoura 
et al., 2004). 
 
1.3.3. RTNs in ALS 
 
We showed that G86R mice and patients with sporadic ALS exhibit a specific 
pattern of Nogo expression in skeletal muscles [Article 2]. High levels of Nogo-A 
protein were found in ALS patients, whereas Nogo-A had been barely detectable in 
muscles of normal subjects, of primary muscle disease and of polyneuropathy 
patients. Moreover, our team has recently demonstrated that Nogo-A 
immunoreactivity in skeletal muscle correlates with the severity of motor impairment 
as assessed by the ALSFRS, and with the degree of muscle fibers atrophy in patients 
with sporadic ALS (Jokic et al., 2005). These observations suggest that Nogo-A 
expression in muscle could be used as a marker of ALS functional disability and in 
monitoring the disease-modifying effects during therapeutic trials. 
 
1.3.4. RTNs are linked to differentiation processes 
 
Many alterations in RTNs expression have been linked to differentiation, both 
in nervous and muscle tissues. Indeed, RTN1 proteins are considered to combine a 
high sensitivity with a high specificity for detection of neuroendocrine differentiations 
in lung cancer (Senden et al., 1997a). Moreover, RTN1-C expression is strongly 
correlated with the degree of neuronal differentiation in human neuroblastoma cell 
lines (Hens et al., 1998), and is also up-regulated during aging of primary cultures of 
cerebral cortical neurons (Li et al., 2002) and down-regulated after maturation of the 
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optic nerve (Kumamaru et al., 2004). We showed that RTN3 and Nogo proteins 
increased during cerebellar development and during in vitro development of 
cerebellar granule neurons, and decreased during in vitro cell death [Article 1]. 
Denervation, which is known to be associated with reactivation of myogenic or de-
differentiation events that come into play to compensate muscle atrophy, cause 
decreased Nogo-C and increased Nogo-A expression in skeletal muscle (Magnusson 
et al., 2003). We recently observed up-regulation of Nogo-C and RTN3-C in skeletal 
muscle following birth and during in vitro differentiation of primary myoblasts [Fergani 
et al., in revision]. Therefore, some of the RTN expression alterations observed in 
pathological cases might reflect the differentiation or de-differentiation component of 
the disease associated with the degenerative changes. 
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2. Uncoupling protein 3 is a potential marker of ALS 
 
2.1. Uncoupling protein family 
 
Uncoupling proteins (UCPs) belong to the superfamily of mitochondrial anion-
carrier proteins. Up to five different uncoupling protein types (UCP1, UCP2, UCP3, 
UCP4 and UCP5/BMCP1) were found in mitochondria of mammals and plants, and 
have also been described in fishes, fungi and protozoa. The archetypal uncoupling 
protein, UCP1, formely known as thermogenin, is mainly found in brown adipose 
tissue and mediates proton leak in brown adipocytes to produce heat in response to 
cold exposure. UCP2 and UCP3 have high sequence identity with UCP1 (Borecky et 
al., 2001) and were isolated as homologues of UCP1 (Fleury et al., 1997; Gimeno et 
al., 1997; Boss et al., 1997; Vidal-Puig et al., 1997; Gong et al., 1997). Originally it 
was thought that these additional UCPs functioned in a thermoregulatory manner 
similar to UCP1, but their uncoupling activity is still debated and their physiological 
function remains still unknown (Goglia & Skulachev, 2003; Jaburek et al., 2004; Boss 
et al., 2000). 
 
2.2. UCP2 and UCP3 expression is increased in ALS muscle 
 
Studies on UCP2 (Arsenijevic et al., 2000) and UCP3 knockout mice (Gong et 
al., 1997; Vidal-Puig et al., 1997) showed that these proteins might be involved in the 
regulation of mitochondrial respiration and that this function might deal with the 
resistance to oxidative stress. Since growing evidence points to mitochondrial 
dysfunction as playing a crucial role in ALS pathogenesis [(Gonzalez de Aguilar et 
al., 2005) for review] and that damage by reactive oxygen species (ROS) is involved 
in ALS, we monitored UCPs expression pattern in ALS [Article 3]. We showed that 
UCP2 and UCP3 are increased in ALS skeletal muscle, both in G86R mice and in 
human ALS biospsies. Since UCP3 induction was not observed in muscle biopsies of 
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polyneuropathies and primary muscle diseases patients, UCP3 is a potential marker 
of ALS. 
 
2.3. UCP3 is a potential modulator of reactive oxygen species 
metabolism in ALS 
 
ROS regroup molecules such as superoxide anion, hydroxyl radical and 
hydrogen peroxide, possess strong oxidative capacity and are normal by-products of 
mitochondrial respiration. However, ROS produced in excess can mediate cellular 
damage, which is known to contribute to ALS pathogenesis [(Simpson et al., 2003) 
and (Liochev & Fridovich, 2003) for review]. The potential role for UCP3 in 
modulating ROS formation in muscle is supported by many studies. For instance, 
mice lacking UCP3 exhibited an increase in ROS level in their muscles (Vidal-Puig et 
al., 2000) and increased UCP3 expression associated with hyperoxia-mediated 
oxidative stress was recently reported, both in mouse muscle and in C2C12 
myotubes (Flandin et al., 2005). Moreover, a role for UCP3 in the regulation of ROS 
production also fits with the finding that UCP3 expression decreases with aging in 
mitochondria isolated from rat skeletal muscle, because aging has been associated 
with increased ROS production (Kerner et al., 2001). Furthermore, UCP3 induction in 
human skeletal muscle after acute exercise (Pilegaard et al., 2000) could serve to 
prevent the well-known increase of ROS production during exercise. In the light of 
these findings, we hypothesize that UCP3 induction we observed in ALS muscle 
might participate in a counter-regulatory mechanism to lower the production of ROS 
due to oxydative stress, through a yet unkown mechanism but possibly in a manner 
that is independent of mitochondrial uncoupling (Maclellan et al., 2005). Therefore, 
UCP3 induction might be among the numerous intracellular antioxydant defences 
already observed in ALS muscle [Article 4]. It is also worth emphazing that ROS at 
their turn might regulate UCP3 activity (Echtay et al., 2002), which could contribute to 
the antioxidant response of ALS muscle. 
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2.4. UCP3 is a potential mediator of hypermetabolism in ALS 
 
Growing evidence points to metabolic perturbations as playing an important 
role in ALS. Creatine, an intracellular energy shuttle between mitochondria and sites 
of energy consumption, extends the life expectancy of G93A mice (Klivenyi et al., 
1999). Our team has shown important variations in a number of metabolic indicators 
in G86R mice, which in all shows a metabolic deficit (Dupuis et al., 2004). These 
alterations were accompanied early in the asymptomatic phase of the disease by 
reduced adipose tissue accumulation, increased energy expenditure, and 
concomitant skeletal muscle hypermetabolism. Compensating this energetic 
imbalance with a highly energetic diet extended mean survival by 20%, a significant 
effect when compared to other beneficial treatments (Dugan et al., 1997; Gurney et 
al., 1996; Zhu et al., 2002). In addition, at least a subset of ALS patients shows a 
characteristic hypermetabolism phenotype (Kasarskis et al., 1996; Desport et al., 
2001), reminiscent of that observed in G86R mice. It is also worth emphasizing that 
the nutritional status is a prognostic factor for survival in ALS (Desport et al., 1999), 
and that an appropriate, individualized nutritional management of patients may 
constitute a primary symptomatic treatment for the disease (Cameron & Rosenfeld, 
2002). 
Many studies provided evidence for the in vitro (Gong et al., 1997; Vidal-Puig 
et al., 2000; Clapham et al., 2000) and in vivo (Cline et al., 2001) uncoupling activity 
of UCP3. Moreover, this uncoupling activity is already known to mediate 
hypermetabolism responsible of hyperphagy and leanness of muscles from 
transgenic mice that overexpress UCP3 (Clapham et al., 2000). In ALS, existence of 
mitochondrial uncoupling is suggested by decreased respiratory control ratio of 
isolated mitochondria and decreased levels of ATP in G86R muscle tissue [Article 3], 
and other indirect evidence (Carri et al., 1997). Therefore, UCP3 induction may 
participate to the hypermetabolism observed in ALS through mitochondrial 
uncoupling. However, the mechanism by which UCP3 uncouples mitochondria is still 
under debate (Klingenberg et al., 1999; Jezek et al., 1998) and further studies are 
needed both to validate the link between muscular induction of UCP3, mitochondrial 
uncoupling and hypermetabolism, and to determine the role of hypermetabolism in 
ALS pathogenesis. 
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3. Expression profiling of skeletal muscle in patients affected by 
ALS  
 
3.1. The microarray approach 
 
Microarrays, a recently developped technology, have known a tremendous 
progress and have become a revolutionary platform for the study of gene expression, 
as can be seen from the exponential increase in the number of research articles 
using microarray-based technology (Fig. 8). Microarray-based investigations, 
combined with advanced bio-informatics, hold tremendous potential both in the study 
of biological processes in disease and in molecular diagnosis. Notable examples 
include the identification of genes that classify subtypes of cutaneous melanoma 
(Bittner et al., 2000); genes that predict survival for diffuse large B-cell lymphoma 
(Shipp et al., 2002; Alizadeh et al., 2000), breast cancer (Perou et al., 2000; Sorlie et 
al., 2001; van 't Veer et al., 2002) and lung adenocarcinoma (Beer et al., 2002); and 
genes that open new therapeutic targets for MS (Lock et al., 2002).  
 
3.2. The technology of microarray 
 
A glossary of common terms in microarray litterature used in this section is 
provided (see term*). Microarrays*, also known as biochips, DNA chips and gene 
chips, may be described as an ordered array of microscopic elements on a planar 
surface that allows the specific binding of genes or gene products (Schena, 2002). 
An effective microarray requires that all analytical elements have their own unique 
address and are equally sized and uniformly configured. This allows accurate 
identification during analysis and subsequent ease in examination and quantification. 
Various types of microarrays have been produced based on their target material,  
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Fig. 8. Number of microarray based publications since 1995. 
Analysis performed on PubMed database. 
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which can be cDNA, mRNA, protein, small molecules, tissues or any other material 
that allows quantitative gene analysis. We used high-density oligonucleotide 
microarrays (Lockhart et al., 1996), manufactured by Affymetrix and commercially 
named GeneChips, which will be the common name used here. Two nomenclatures 
exist regarding the definition of “target”* and “probe”*. Certain authors use the term 
“target” to describe the molecule that is attached to a microarray substrate and reacts 
with the free “probe” which is in solution. Here, “target” has been defined as the free 
nucleic acid and “probe” as the nucleic acid attached to the microarray substrate. 
The GeneChip used in our experiments was the GeneChip Human Genome 
U133 Set (HG-U133A and HG-U133B) (Table 7 for critical specifications). As 
previously described (Lipshutz et al., 1999), HG-U133 arrays are prepared by 
depositing 25-nucleotide molecules on a quartz surface and two types of probes are 
used, called Perfect Match* (PM) and Mismatch* (MM) probes. The PM probes 
match a target sequence exactly , while its partner probe, the MM probe, differs from 
the PM probe by a single base in the middle of the sequence. PM and MM probes 
are together known as a probe pair, and 11 probe pairs* constitutes a probe set*, 
which is used to investigate different parts of the sequence of the same gene (Fig. 9). 
The expression measure of a determined gene is the average of the information 
obtained from each of the probes in a probeset. 
The technology of GeneChips is characterized by very interesting capabilities: 
i) Sensitivity: arrays are produced with hundreds of thousands of different 
probes packed at an extremely high density, allowing genome-wide data using small 
sample volumes 
ii) Specificity: the PM/MM probe pairs allow the quantitation and substraction 
of signals caused by non-specific cross hybridization, finally indicating specific target 
abundance 
iii) Reproducibility: the design and manufacture of these arrays are highly 
stereotyped and consistent, providing a high degree of reproducibility between 
experiments and enabling independent examination of the same gene in the 
experiment. 
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Number of array in Set 2
Number of probesets >45 000
Number of transcripts ~39 000
Number of genes ~33 000
Number of features >1 000 000
Feature size 18 m
Oligonucleotide probe length 25 mers
Probe pairs/sequence 11
Housekeeping/control genes GAPDH, beta-actin, ISGF-3
Databases used in the design of the array 2,7 million input sequences selected from GenBank, dbEST, RefSeq
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Critical specifications of GeneChip Human Genome U133 Set (From 
Affymetrix website) 
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Fig. 9. GeneChips content. 
a. Oligonucleotides of 25 base pairs are synthesized onto a quartz support of 
1.28x1.28 cm. Several millions identical 25mers fit into a feature or a probe cell of 
about 18 m. 
b. The organization of an array is as follows. One transcript is quantified by one
probe set and a single array may contain probe sets for more than 40,000 human 
genes and ESTs. One probe set is composed by 11 probe pairs. One probe pair is 
composed by a perfect match (PM) probe cell and a mismatch (MM) probe cell. A PM 
probe is an oligonucleotide that is complementary to a transcript and a MM probe is 
an oligonucleotide with the corresponding sequence containing a point mutation. 
Oligonucleotide probes are chosen based on uniqueness criteria and composition 
design rules. The use of the differences averaged across a set of probes greatly 
reduces the contribution of background and cross-hybridization. 
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3.3. Gene expression experiment 
 
We analysed deltoid muscle biopsies obtained from ten ALS patients (from 
Prof. Vincent Meininger's Service - Hôpital Pitié-Salpétrière) and from ten controls 
without nervous system pathology (from Banque de Tissus pour la Recherche - 
Association Française contre les Myopathies). All ALS patients were in early stages 
of the disease, except for two patients more advanced in the pathology (see Table 8 
for clinical features of ALS patients and control subjects). 
One of the major concerns in microarray profiling studies of clinical samples is 
the effect of tissue sampling and RNA extraction on data. To keep variations from 
technical sources at minimum, muscle biopsies were collected by the same surgeon 
(one for ALS patients, another one for control subjects), snap-frozen within 1 minute 
following surgical resection and stored until RNA extraction in liquid nitrogen. In 
addition, special attention was taken at each step of the target preparation to protect 
RNA against high temperature, temperature changes and RNases. For fibrous 
tissues such as skeletal muscle, the most difficult step in the isolation process can be 
complete disruption of all the cells when preparing tissue homogenates. Due to low 
cell density and the polynucleate nature of muscle tissue, biospies are indeed difficult 
to homogenize completely and can result in degraded RNA and very low yield. To 
overcome these difficulties, we extracted total RNA using the FastPrep® system (Fig. 
10 for the overall RNA extraction procedure). Total RNA and cRNA target quality 
were assessed using the Agilent Bioanalyzer system as described in Fig. 11. Purified 
total RNA served as template to synthesize the biotin-labeled cRNA target, and 
GeneChips were scanned after target hybridization and automated chip 
washing/staining (Fig. 12). Images obtained from the chips were computated as 
described in the next section.  
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ALS
patients
age
(years) gender
disease
duration
(days)
ALSFRS
score
right arm
abduction
score
control
subjects
age
(years) gender
1 52 M 491 43 5 1 50 M
2 36 M 371 40 4 2 55 F
3 54 M 194 41 5 3 65 F
4 48 M 425 28 1 4 57 M
5 50 M 576 42 5 5 45 F
6 62 M 401 43 5 6 18 M
7 60 M 400 42 5 7 48 F
8 49 M 491 28 2 8 60 F
9 58 M 491 45 4 9 29 M
10 54 M 221 43 4 10 25 M
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Clinical features of the ALS patients and control subjects analysed by 
GeneChips 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of ALS patients were in early stages of the disease, as indicated by high 
ALSFRS scores (between 40 and 45). Patient n°4 and n°8 are more advanced in the 
pathology, as can be seen from their low ALSFRS scores (28). 
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Fig. 10. Total RNA isolation from deltoid muscle biopsies (Adapted from Q-
BIOgene website). 
The FastPrep system (Q-BIOgene) is characterized by very interesting capabilities. This 
method replaces cumbersome alternatives such as vortexers, mortar and pestle, sonicators 
and blenders. It enables rapid and consistent lysis, in a self-contained and easy-to-use 
system. 
RNA isolation protocol: muscle biopsies stored in liquid nitrogen were added frozen on a Bio 
101 FastRNA green tube (Q-BIOgene) preloaded with 1 ml Trizol  (Invitrogen). 
Homogeneisation (force 6, 40 seconds) was performed in a FastPrep FP120 (Savant). After 
5 minutes on ice, 0.2 ml chloroform was added and homogenized by strong vortexing. After 
15 minutes centrifugation (full speed, 4°C), total RNA in acqueous phase was precipitated 
with isopropanol. On average, 38 µg total RNA was isolated and then purified using RNeasy 
Mini-Spin columns (Qiagen) employing standard protocols provided by the manufacturer: 350 
µl RLT buffer was mixed with the total RNA; after adding 250 l of 70 % ethanol and pipetting 
up and down, the mixture was loaded onto an RNeasy column, washed and eluted in 50 l 
distilled water. Volume was reduced to 11 µl using a speed-vaccum. On average, 24 µg 
purified total RNA was recovered. 
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Fig. 11. Total RNA and cRNA target quality assessment. 
RNA samples from deltoid muscle biopsies were analysed for their concentration and 
overall length using the Agilent Bioanalyzer RNA Chip. Fluorescence intensities are 
plotted against migration time in seconds for total RNA (a) and for cRNA (b). Virtual 
gels of the total RNA (c) and of the cRNA (d) samples are shown with molecular 
weight markers indicated on the left of each panel. 
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Fig. 12. Gene expression assay. 
Total RNA is first reverse transcribed using a T7-oligo(dT) promoter primer in the 
first-strand cDNA synthesis reaction. Following RNase H-mediated second-strand 
cDNA synthesis, the double-stranded cDNA is purified and used as a template in the 
subsequent in vitro transcription (IVT) reaction. The IVT reaction is carried out in the 
presence of T7 RNA polymerase and a biotinylated nucleotide analog/ribonucleotide 
mix for complementary RNA (cRNA) amplification. The biotinylated cRNA targets are 
then cleaned up, fragmented, and hybridized to GeneChip expression arrays. The 
hybridized probe array is then washed and stained by a streptavidin-phycoerythrin
fluorescent mix. Finally, the probe array is scanned and the obtained image is 
processed for data quantitation. 
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3.4. Data quantitation 
 
Data quantitation* is a computer executed task, involving translation of signal* 
intensities obtained from microarrays into numerical values. It involves making 
appropriate corrections for values obtained from the sample (signal), while taking into 
account unwanted intensity values from the microarray surface, or due to differences 
in probe binding, fluorescence… (commonly referred to as background). In our 
experiment, images of the scanned GeneChips were stored in data files (.dat) using 
Microarray Analysis Suite 5.0 (MAS; Affymetrix), and visualized on screen to detect 
possible abnormalities. Then, MAS created cell intensity files (.cel), by aligning a grid 
on the image, assigning each cell to an x, y coordinate position, attributing to each 
cell the corresponding probe set characteristics, and calculating the average intensity 
of each cell. The .cel files were used to re-analyze data with programs developed in 
R 1.8.0 [(Ihaka & Gentleman, 1996), http://www.r-project.org], a programming 
language and developer environment for statistical computing and graphics. 
 
3.5. Data normalization 
 
Normalization* is a necessary and useful step, that basically brings readings of 
all experiments to be on the same scale [(Bolstad et al., 2003) for review]. Actually, 
all endeavours  in microarray data analysis are directed towards the interpretation of 
inherent differences between samples, often called biological variations. These 
variations are often obscured by the introduction of erroneous data, often referred as 
technical or obscuring variations, that are largely the result of differences in 
experimental procedures such as labelling, hybridization* and washes, disparities 
between chips and variations in detection procedures. Normalization is the process 
that corrects for these imbalances in the data. For data normalization, background 
correction and summarization, we used the Robust Multichip Average (RMA) method 
(Irizarry et al., 2003), available as part of the R package Affy, which is a part of the 
Bioconductor project (http://www.bioconductor.org). RMA algorithm, based on the 
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quantile method, seems to perform favorably both in terms of speed, variability and 
bias, when compared to other algorithms (Bolstad et al., 2003). 
 
3.6. Data mining and modelling 
 
The overall data mining approach we used in our experiment is shown in Fig. 
13. Data mining* and modelling represents the most important and challenging step 
in reaching an accurate and meaningful biological conclusion from microarray data. 
The two central issues involved are the meaningful interpretation of the magnitude of 
gene expression changes and grouping genes based on some common properties. 
Magnitude of gene expression changes and filtering these genes upon this 
magnitude represents the baseline of data mining and modelling. Filtering methods 
may use either heuristic algorithms*, such as "the fold approach"* and "the signal 
threshold approach"*, or statistical algorithms, including parametric tests* such as the 
t-test method* and the analysis of variance*, and nonparametric tests*, such as the 
Wilcoxon-Mann-Whitney test* and the Kruskal-Wallis test*. Choice among the 
numerous existing statistical tests depends on certain features including samples 
number, data distribution, variance equality for each compared group, and number of 
compared groups. Given the typically heterogeneous nature of the human samples 
analyzed in our experiment, we chose an heuristic approach by filtering transcripts 
upon their variance (Fig. 14). Thus, we kept only those transcripts whose standard 
deviation over all samples was greater than 0.3. Only 3,340 transcripts survived this 
thresholding operation and served for further analysis. 
Gene clustering, the process of grouping together similar genetic elements, is 
important because it has been noticed that genes sharing a common role in cellular 
processes, and genes with high degrees of sequence identity tend to be clustered 
together (Eisen et al., 1998). Clustering approahes can be either unsupervised or 
supervised. The former method does not use any known reference vectors while the 
latter is based on a known vector (Brazma & Vilo, 2001; D'Haeseleer et al., 2000). 
We used the unsupervised Coupled Two-Way Clustering (CTWC) approach (Getz et  
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Fig. 13. Data mining. 
Data mining steps are indicated in blue. We isolated only those transcripts whose 
standard deviation over all samples is greater than 0.3. We used the Coupled Two-
Way Clustering (CTWC) approach to group the 3,340 transcripts that survived this 
thresholding operation according to their expression profile. This clustering analysis 
converged to 9 stable gene clusters (G2-G10), and each of these clusters was used 
to cluster the samples. Two of these sample partitions had clear biological meaning: 
sample clustering using G3 and sample clustering using G9. Genes contained in G3 
and G9 (in red) were further analyzed in detail. 
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      Fig. 14. Steps of gene filtration on standard deviation. 
 
 
 
 
 83 
al., 2000; Blatt et al., 1996). The main idea of CTWC is to identify subsets of genes 
and samples such that when one of these is used to cluster the other, stable and 
significant partitions emerge. In our hands, the 3,340 regulated transcripts were 
clustered according to their expression level similarities among the twenty samples 
analysed (Fig. 15a). This clustering analysis converged to 9 stable gene clusters* 
(G2-G10) and 25 stable sample clusters (S2-S26). Then, sample clustering was 
performed using each of the 9 stable gene clusters.Two of these partitions had clear 
biological meaning: sample clustering using G3 and sample clustering using G9.  
 
3.7. Sample clustering using G3 
 
Clustering analysis using the gene cluster G3 showed that ALS samples are 
grouped alltogether in a stable sample cluster (S6) and clearly separated from the 
controls (Fig. 15b). Expression of the genes contained in G3 is lower in ALS samples 
than in controls (Fig. 16a). Indeed, after a Permutation Test* performed on the signal 
of each gene between ALS samples and controls, the p-value was less than 5% for 
15 genes out of the 16 genes analysed (Fig. 17 for a representative example). 
 
3.8. Sample clustering using G9 
 
Clustering analysis using the gene cluster G9 showed that 4 ALS samples are 
grouped together with all controls in a stable sample cluster (S22) (Fig. 15c). 
Expression of the genes contained in G9 is higher in the 6 other ALS samples than in 
sample cluster S22 (Fig. 16b). In addition, after a Spearman correlation test* 
performed between the signal of each gene for the ten ALS patients and their arm 
abduction testing score (Fig. 3b), the p-value is less than 5% for 251 genes out of the 
274 genes contained in G9 (Fig. 18 for a representative example). 
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Fig. 15. Unsupervised classification analysis of ALS and control samples. 
a. Gene expression matrix* obtained by coupled-two way clustering of gene expression 
profiles using the 3340 regulated genes. Each row represents a gene and each column 
represents a sample. Expression data for gene clusters G3 and G9 in all samples are 
indicated by two black boxes. The color scale represents levels of expression, ranging from 
low (blue) to high expression (red) (see color bar on the bottom right). 
b and c. Dendogram* of sample clusters using either gene cluster G3 (b) or gene cluster G9 
(c). Sample clusters are shown as boxes. Stable sample clusters* are indicated by an arrow 
and are coloured either in light blue, in orange or in red. The vertical axis is the 
"temperature" parameter* T. On the horizontal axis, the samples are ordered according to the 
dendogram. The bar at the top of the dendograms represents the order of the samples, with 
control samples represented by triangles and ALS samples represented by circles. Patient 
number is also indicated under the figures. 
b. When the genes of G3 are used, clear separation between ALS and control samples is 
obtained. Stable cluster S6 includes all ALS samples (red circles) and stable cluster S7
includes 6 control samples (orange triangles). 
c. When the genes of G9 are used, all control samples (red triangles) together with 4 ALS 
samples (red circles) are clustered in the stable cluster S22. This cluster is clearly 
separated from the other ALS samples (white circles). 
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Fig. 16. Reordered data for gene cluster G3 (a) and gene cluster G9 (b). 
Each row represents a sample ("sla" for ALS samples and "ct" for control samples) 
and each colomn represents a gene (16 genes for G3 and 274 genes for G9). Each 
row includes the expression levels in a given sample. Samples are ordered as shown 
in Fig. 15. The color scale represents levels of expression, ranging from low (blue) to
high expression (red) (see color bar on the right). 
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Fig. 17. mRNA levels of gene X (from gene cluster G3). 
Gene X signal is represented in each of the ten patients with ALS (dark triangles) and 
ten control subjects (white circles). ** = p < 0.01, with p = permutation test p-value 
between ALS and control groups. Horizontal bars are mean values. 
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Fig. 18. mRNA levels of gene Y (from gene cluster G9). 
On the left, gene Y signal is represented in each of the ten ALS patients compared to 
their respective arm abduction testing scores. On the right, gene Y signal is figured in 
each of the ten control subjects and indicated by the arrow. r = Spearman correlation 
coefficient. Note that the correlation is negative.   
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3.9. Data annotation 
 
After isolating probesets from gene cluster G3 and G9 that corresponded to 
known genes (excluding  Expressed Sequence Tags* (ESTs)) and grouping them by 
Unigene* cluster, we performed a manually searching in databases for each probeset 
to make accurate functional interpretation of our data set (Fig. 19). We centralized 
useful information in an Excel data sheet as shown in Table. 9. We used the NetAffx 
web portal (Liu et al., 2003) to retrieve static probeset information and sequence 
annotations from the HG-U133 Target Databank*. This information included the 
representative sequence available in GenBank* and RefSeq*, the Unigene cluster 
identifier for the associated gene (Schuler, 1997), the Online Mendelian Inheritance 
in ManTM* identifier (OMIM) (McKusick, 1998), the Gene Ontology* (GO) terms 
(Ashburner et al., 2000; Cheng et al., 2004), and GenMAPP* (Dahlquist et al., 2002) 
and Kyoto Encyclopedia of Genes and Genomes* (KEGG) (Wixon & Kell, 2000) 
pathways. Using PubMed, each transcript was assigned with data from the literature 
that might be relevant in the context of ALS and references of major papers 
concerning the hit. In addition, we added the corresponding murine sequences and 
expression data available in the lab on the hit in asymptomatic and symptomatic 
G86R mice. Finally, we assigned a number ranging from 1 to 4 illustrating the level of 
relevance for the hit. 
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Fig. 19. Data annotation of gene cluster G3 and G9.   
Databases used are indicated in blue. 
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Gene Title Gene Symbol HG-U133ProbeSet ID
GeneBank ID
RefSeq ID
MG-U74Av2
ProbeSet ID
GeneBank ID
RefSeq ID UniGene ID OMIM ID
Fold Change
mSOD1 mice
axo mice
calpain 2, 
(m/II) large 
subunit
CAPN2 208683_at M23254NM_001748 101040_at D38117
Hs.350899
Mm.6958 114230
nc sod75d
up sod105d 1,7
up axo 2,1
GO biology GO function GO cellular 
component
KEGG / 
GenMAPP
Pathway
Notes PubMed references Relevance level
proteolysis and 
peptidolysis
calpain activity
calcium ion binding
hydrolase activity
intracellular
Nonlysosomal intracellular calcium-activated 
cysteine protease.
CAPN3 is muscle-specific.
Calpain inhibitors has provided 
neuroprotection in models of spinal cord 
injury.
Calpain 1 and calpain 2 mRNA increase in 
progressive muscular dystrophy and ALS 
patients.
PD150606,  a selective calpain antagonist, 
inhibits KA-induced motor neuron death, but 
not via calpain inhibition.
Physiol Rev. 2003 
83:731-801
Brain Res Brain Res Rev. 
2003 42:169-85
Physiol Rev. 2000 
80:1215-65
J Neurol Sci. 1998 
155:163-9
Neuropharmacology. 
2002 42:706-13
1
 
 
 
 
     Table. 9. Example of data annotation for a gene contained in cluster G9   
 
 
 
ID: identifier. up/nc/down: gene up-regulated/not regulated/down-regulated compared 
to the control group. sod: SOD1 G86R mice. axo: axotomized mice. 75/105d: 75/105 
days old. 
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3.10. Microarray expression data validation 
 
Three genes from gene cluster G9 and G3 were arbitrarily selected to verify 
microarray expression data. The expression of these genes was examined by QPCR 
in 12 of the control and ALS samples. The same RNA sample used for microarray 
experiments was analysed. The 18S ribosomal RNA was used as control for sample 
loading in both microarray and QPCR experiments. The relative amounts of the three 
mRNAs evaluated by QPCR strongly correlated with the microarray-based 
measurements (Fig. 20). Besides, some genes contained in these clusters are 
already known to be regulated in ALS, including calpain 2 [(Ueyama et al., 1998), 
Table. 9 and Fig. 21] and thioredoxin (Malaspina et al., 2001; Ogawa et al., 1997). 
These data further supports the reliability of the experimental approach. 
 
3.11. An example of application: retinoic acid metabolism in ALS 
 
Surprisingly, several hits emerging from our data analysis were linked to 
retinoic acid (RA) metabolism (Fig. 22). Among them, the retinaldehyde 
dehydrogenase 2 (RALDH-2), that convert the retinal derived from ingested -
carotene to RA, the RA binding protein I (CRABP-I), that binds RA in the cytoplasm, 
and P450RAI (CYP26), a cytochrome P450 enzyme that specifically metabolizes RA 
and channels RA towards catabolic pathways, are differentially regulated in ALS 
muscle according to our GeneChip experiment (Fig. 23). Although the biological 
meaning of these regulations in an ALS context needs exhaustive research, it is 
worth emphasizing that very early studies already reported nerve lesions induced by 
defects in the retinoid signalling pathway (Irving & Richards, 1938; Hughes et al., 
1924). Moreover, retinoid-deficient rats exhibit phenotypes reminiscent of those 
observed in ALS patients, including accumulation of neurofilament and vacuolar 
lesions in motor neurons in the spinal cord, loss of motor neurons and increased  
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Fig. 20. Correlation analysis of data obtained from GeneChips and quantitative 
PCR (Q-PCR).  
The ratio mRNA to 18S rRNA was determined for both GeneChips and QPCR 
experiments. The relative values for each gene from 7 ALS (dark triangles) and 5 
control samples (white circles) are shown. r = Pearson correlation* coefficient. 
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Fig. 21. Calpain 2 contained in cluster G9 is already known to be regulated in 
ALS muscle. 
On the left, mRNA levels of calpain 2 (normalized by mRNA level of -actin) 
measured by Q-PCR in biceps muscle biopsy from control subjects (white circles) 
and from patients with progressive muscular dystrophy (PMD - dark circles) and ALS 
(white circles). Results from Ueyama et al., 1998. 
On the right, calpain 2 signal measured in our GeneChip experiment is represented 
in each of the ten patients with ALS (dark triangles) and ten control subjects (white 
circles). Horizontal bars are mean values. 
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Fig. 22. Retinoic acid metabolic pathway. 
Retinylesters and -carotene are ingested and converted to retinol (ROL) in the 
intestine by ,-carotene-15,15'-oxygenase (BCO) activity. ROL is then reconverted 
to retinyl esters for storage, mainly in the liver. Demand for ROL results in the release
of ROL that is bound to plasma retinol–binding protein (RBP) from the liver.
Conversion of ROL to the active forms of retinoic acid (RA) occurs in many different 
tissues, including skeletal muscle. RA is converted from ROL precursor by a 
conversion to retinaldehyde (RAL) by alcohol dehydrogenase (ADH) activity and 
subsequently to RA by retinaldehyde dehydrogenase 2 (RALDH-2) activity. RA is 
bound in the cytoplasm by cellular RA-binding proteins (CRABP). RA will act on RA 
nuclear receptors (RARs and RXRs) to activate the expression of RA responsive
genes. This activity can be blocked if RA-metabolizing enzymes, such as P450RAI 
(CYP26), are present, channeling RA towards a catabolic pathway. In our GeneChip 
experiment, genes are indicated in red when induced and in blue when repressed. 
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Fig. 23. Regulated genes involved in retinoic acid metabolic pathway. 
Retinaldehyde dehydrogenase 2 (RALDH-2),  cellular retinoic acid-binding proteins 
(CRABP1 and 2) and P450RAI (CYP26) signals are indicated as mean values in the
ten patients with ALS (in dark) and ten control subjects (in white). ** = p < 0.01, * = p 
< 0.05 with p = student test p-value between ALS and control groups.   
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reactive astrocytosis in the lumbar cord (Corcoran et al., 2002). In patients suffering 
from spontaneous motor neuron disease, defects in the retinoid signalling pathway 
were also found (Corcoran et al., 2002), including decreased raldh-2 expression in 
motor neurons of diseased spinal cord. These results suggest that a defect in the 
retinoid signalling pathway might have a role in ALS pathogenesis. 
Although serum and plasma levels of vitamin A are normal in ALS (Molina et 
al., 1999; Iwasaki et al., 1995; Bonnefont-Rousselot et al., 2000), several links 
between retinoic acid metabolism and ALS pathogenesis might be speculated. 
Vitamin A and analogues are potential antioxidant factors, notably through their 
characteristic chemical and physical properties [(Demmig-Adams & Adams, 2002) for 
review]. It has been shown that retinol, retinol acetate, RA, retinol palmitate, and 
retinal protect neuronal membranes from lipid peroxidation by free radicals (Das, 
1989). Moreover, RA inhibits hydrogen peroxide-induced apoptosis via suppression 
of c-fos/c-jun expression and c-Jun N-terminal kinase activation in glomerular cells 
(Kitamura et al., 2002). It has also been shown that binding of the peroxisome 
proliferator-activated receptor to the SOD1 promoter was increased by treatment with 
RA and 9-cis RA (Yoo et al., 1999). Therefore,  RA might act coordinately with others 
molecular effectors in preventing the increased oxidative stress in ALS muscle. RA is 
also widely described as an active player in the regeneration of several tissues and 
organs [(Maden & Hind, 2003) for review]. Notable examples include stimulation of 
neurite outgrowth, via induction of RA synthesis by nerve growth factor (Corcoran & 
Maden, 1999); regulation of cell growth and differentiation of the vascular system 
[(Gardner & Chen, 1999; Miano & Berk, 2000; Neuville et al., 2000) for review], 
possibly via stimulation of VEGF release in smooth muscle cells (Tanabe et al., 
2004); and multiple implications in myogenic cascades (Busson et al., 2005; Mic & 
Duester, 2003; Shin et al., 2000; Georgiades & Brickell, 1997; Larrain et al., 1997; 
Xiao et al., 1995). Therefore, alterations in muscular RA pathway might reflect the 
differentiation or de-differentiation component of the ALS disease. Finally, it is also 
worth emphasizing that muscle UCP3 expression is up-regulated in mice following 
dietary vitamin A supplementation and acute RA treatment (Felipe et al., 2003). 
These findings together with our present data presage an important role of the 
retinoid signalling pathway in ALS pathogenesis., and research in this field is 
currently in progress in our laboratory. 
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Conclusion and 
Perspectives
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The microarray approach we conducted in muscle biospies from ALS patients 
has enabled the creation of a database in which genes are systematically profiled to 
constitute a molecular identity card of skeletal muscle affected by the disease. We 
are currently exploiting this database following three main lines of research. 
 
New progression markers of ALS 
 
Markers of ALS progression need tight correlation between the measured 
signal intensity and clinical measures as motor strength or vital capacity, observer-
independent quantification, strong and linear changes in signal intensity during the 
disease progression, a procedure allowing serial examinations in the same patient 
non-invasively, and ideally a protocol that is cheap and rapidly applied to a large 
number of subjects. Genes included in cluster G9 fulfill at least several of these 
criteria: their signal intensities correlate with a testing score, gene expression 
measurements are relatively independent from the bench scientist and are easily 
applied to a large number of samples. Similarly, Nogo-A is a potential marker of ALS 
progression, since protein levels of Nogo-A dramatically increase in ALS skeletal 
muscle and correlate with the ALSFRS scale. However, these preliminary markers 
need to be confirmed in a larger patient group and followed during longitudinal 
clinical studies.  
 
New diagnostic tools for ALS 
 
In contrast to progression markers, early diagnostic markers need specificity of 
the observed signal for ALS. Moreover, they also need high sensitivity so that 
patients in early or ideally in preclinical disease stages may be screened. In this 
context, genes included in cluster G3 and UCP3 are interesting candidates insofar as 
their expression may appear highly and precociously regulated, as compared either 
to normal subjects or to patients affected by other neurological or muscular diseases. 
However, comparisons with many other ALS-like syndromes are still needed to affirm 
specificity of these markers. In addition, diagnostic procedures need to be refined, 
standardized and financially optimized to become a routine diagnostic tool. Such 
specificity and sensitivity explorations are already launched both in a clinical context, 
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in collaboration with the service of Prof. Vincent Meininger (Hôpital de la Pitié-
Salpétrière, Paris), and in our laboratory. In particular, we have performed 
GeneChips analyses of skeletal muscle from G86R mice and from axotomized mice 
that modelize acute denervation. These investigations will give us access to very 
precocious genetic modifications that might appear prior to overt symptoms. They will 
also contribute to identify gene regulations accompanying neurogenic atrophy, and 
will enable us to cross results between ALS patients and a widely studied model of 
ALS. In addition, "Meta-analyses" using the existing and ever increasing pool of gene 
microarray databases (easily accessible via the Gene Expression Omnibus* data 
repository of the National Center for Biotechnology Information) would enable us to 
exclude genes not related specifically to ALS. For example, microarray databases 
are available on transcriptional adaptations underlying skeletal muscle atrophy, which 
is a common response to many disorders (Jagoe et al., 2002; Stevenson et al., 2003; 
Lecker et al., 2004; Kostrominova et al., 2005). 
 
New genes involved in ALS pathogenesis 
 
Exploring our database might shed light on the pathogenic mechanisms of 
ALS. Particularly, we identified alterations in the RA signalling pathway that are now 
under investigation. Indeed, we are currently analyzing the expression levels of RA 
signalling-linked genes [(Balmer & Blomhoff, 2002) for classification] in our 
GeneChips murine and human databases. In parallel, we are measuring RA 
concentration in G86R muscle and liver, and we are testing the effects of a RA-
enriched diet on G86R mice. 
As far as Nogo-A is concerned, many studies are currently performed to 
explore its involvement in ALS pathogenesis. In collaboration with the laboratory of 
Prof. Martin Schwab (Brain Research Institute, Zurich), we showed that G86R/Nogo-
A-/- double transgenics, generated by crossing G86R and Nogo-A knockout mice 
(Simonen et al., 2003), survived about 20% more than G86R/Nogo-A+/+ animals 
(Jokic et al., manuscript in preparation). In collaboration with the laboratory of Prof. 
Markus Rüegg (Biozentrum, Basel), we also observed that in vivo overexpression of 
Nogo-A by intramuscular transfection revealed several morphological abnormalities 
at the neuromuscular junction (NMJ) level, including disappearance of pre-synaptic 
terminals, as well as fragmentation of post-synaptic structures (Jokic et al., 
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manuscript in preparation). These findings are reminiscent of that observed in ALS 
patients and in mouse models of ALS (Yoshihara et al., 1998; Fischer et al., 2004), 
and suggest that induction of Nogo-A, as observed in ALS muscle, might interfer with 
nerve sprouting and synapse plasticity. Such changes might induce "destabilization" 
of the NMJ and might, at least in part, contribute to the characteristic denervation of 
ALS. This quite novel concept of "myogenic" insult in ALS, provoked by Nogo-A 
induction or other abnormalities in local retrograde signaling from the skeletal muscle, 
is in accordance with the axonal dying-back model already defended by some 
authors [(Coleman & Perry, 2002; Glass, 2004; Santos & Caroni, 2003) for review]. In 
this model, upstream events specific to ALS would lead to a progressive synaptic 
weakening, which in turn would result in denervation long before the onset of the 
clinical phase and the death of motor neurons (Frey et al., 2000). This is also 
consistent with reports of early transmission defects in a dog model of ALS (Pinter et 
al., 1995) and in ALS patients (Maselli et al., 1993).  
The hypothesis supporting distal injury in ALS could help to the development 
of novel therapeutic strategies. This idea has already been tested by stabilizing the 
NMJ in mouse models of congenital muscular dystrophy (Moll et al., 2001; Bentzinger 
et al., 2005). This kind of approach is also explored in our laboratory by crossing 
G86R mice with animals overexpressing agrin, a key regulator of the formation of 
postsynaptic structures at the NMJ (collaboration with the laboratory of Prof. Markus 
Rüegg). Another strategy would be early treatment of peripheral synapses by 
regenerative agents. These may include the monoclonal antibody raised against 
Nogo-A, IN-1 (Merkler et al., 2001), or neurotrophic factors such as IGF-1 
(Dobrowolny et al., 2005; Kaspar et al., 2003), GDNF (Sagot et al., 1996) and 
neurotrophin-3 (Haase et al., 1997). Targeting motor neuron axon would also 
constitute another interesting approach. Actually, it is surprising that most strategies 
to combat ALS focussing on neuronal cell bodies have little effect (Sagot et al., 1996; 
Sagot et al., 1995). In contrast, strategies that protect motor neuron axons appear 
more efficient (Williamson et al., 1998; Williamson & Cleveland, 1999; Couillard-
Despres et al., 1998). Factors involved in axonal degeneration may be distinct from 
those inducing death of neuronal cell body (Deckwerth & Johnson, 1994; Finn et al., 
2000; Sagot et al., 1995). Therefore, approaches targeting distal injury might have 
been hindered by a lack of appropriate leads to follow (Coleman & Perry, 2002). In 
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this respect, our databases will hopefully fill this gap in the search of new targetable 
molecules. 
 
In conclusion, this PhD work may be considered as a bold and daring step in 
ALS research. Indeed, the concept making skeletal muscle an active player in ALS 
goes against the general trend that largely focus on nervous system. In this context, 
the microarray approach was an interesting tool, since it allowed us to study this quite 
unexplored pathway in an unbiased way, irrespective of any preconception. 
Moreover, knowing the expression pattern of a large number of genes has given us a 
broader and more complete picture of the cellular processes occuring in skeletal 
muscle affected by ALS. Hopefully, such studies will engage new efforts to exploit 
this unending source of information. 
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